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Abstract 
Krzysztof Kamocki 
 
 
 
THE ROLE OF CERAMIDES IN CIGARETTE SMOKE-INDUCED ALVEOLAR 
CELL DEATH 
 
 
 
 
The complex pathogenesis of emphysema involves disappearance of 
alveolar structures, in part attributed to alveolar cell apoptosis. The mechanism 
by which cigarette smoke (CS) induces alveolar cell apoptosis is not known. We 
hypothesized that ceramides are induced by CS via specific enzymatic pathways 
that can be manipulated to reduce lung cell apoptosis. CS increased ceramides 
in the whole lung and in cultured primary structural lung cells. Exposure to CS 
activated within minutes the acid sphingomyelinase, and within weeks the de 
novo- ceramide synthesis pathways. Pharmacological inhibition of acid 
sphingomyelinase significantly attenuated CS-induced apoptosis. To understand 
the mechanisms by which ceramides induce apoptosis, we investigated the cell 
types affected and the involvement of RTP801, a CS-induced pro-apoptotic and 
pro-inflammatory protein. Direct lung augmentation of ceramide caused 
apoptosis of both endothelial and epithelial type II cells. Ceramide upregulated 
RTP801 and the transgenic loss of RTP801 inhibited only epithelial, but not 
endothelial cell apoptosis induced by ceramide. In conclusion, CS induces acid 
sphingomyelinase-mediated ceramide upregulation and apoptosis in a cell-
specific manner, which in epithelial cells involves induction of stress response 
vi 
proteins that may further amplify lung injury. Molecular targeting of amplification 
pathways may provide therapeutic opportunities to halt emphysema progression. 
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1 
A. INTRODUCTION 
 
1. COPD  
The term chronic obstructive pulmonary disease (COPD) covers two 
diseases: chronic bronchitis and emphysema. Chronic bronchitis is characterized 
as a chronic cough for at least three months per year in two consecutive years, 
with increased production of mucus and sputum. Emphysema is defined as an 
abnormal, permanent enlargement of airspaces distal to the terminal bronchiole, 
through the destruction of their walls [1]. There are many risk factors responsible 
for the development of COPD, including tobacco smoke [2], indoor [3] and 
outdoor air pollutions [4], and genetic factors, like cystic fibrosis (CF) and α-1-
antitrypsin deficiency [5] and diet [6]. The processes invoked in the pathogenesis 
of COPD include oxidative stress, inflammation, and matrix proteolysis [7], [8]. In 
addition extensive apoptosis of lung parenchyma leading to alveolar cell 
destruction is involved in the pathogenesis of emphysema [9]. Emphysema is a 
disease with a high mortality and no cure [10] and COPD is the 3rd leading cause 
of death in the US [11]. COPD is becoming an economic burden not only for the 
costs of diagnosis and management, but also for causing disability and early 
death. Only in 2005 the cost of COPD treatment was $38.8 billion [1]. 
 
 
 
2 
1.1. Inflammation in COPD  
 CS is the major factor which causes an inflammatory reaction and many 
kinds of inflammatory cells, including neutrophils, macrophages, and T 
lymphocytes have been documented to be involved in the pathogenesis of COPD 
[12]. Recent data indicate an important role of T lymphocytes and their excessive 
biological activity correlates with COPD progression [13]. Specifically, the 
number of CD3+ and CD8+ T cells was found to be amplified in bronchi [14], 
parenchymal tissue, pulmonary arteries and small airways [15], and the quantity 
of T cells was inversely proportional to predicted FEV1%. In addition, both the 
number of CXCR3+ cells, CXCR3-ligand, and CXCL10 were elevated in the 
lungs of COPD patients. Neutrophils are also involved in pathogenesis of COPD 
via several mechanisms. CS causes rapid PMN recruitment to the lung [16]. 
Granulocyte adhesion and diapedesis are increased due to the over-expression 
of various adhesion molecules, such as ICAM-1 and E-selectin, on inflammatory 
cells and in pulmonary lung vasculature, respectively [17], [18]. Moreover, both 
neutrophils and macrophages discharge a multitude of cytokines and chemo-
attractants, for example IL-8 and LTB4 [19, 20], thereby self-perpetuating 
inflammatory processes. Macrophages, which specialize in the clearance of 
detrimental particles from the lower respiratory system, are increased in number 
in COPD patients and they participate in delineation of specific inflammatory 
phenotypes during its course [21, 22]. Macrophages, as MHC II cell are also 
responsible for the engulfment and presentation of antigens to CD4+ T cells and 
modulating immune responses in the lungs [23]. 
3 
1.1.2. Ceramides and inflammation 
 Inflammatory cytokines such as tumor necrosis factor-α (TNF-α) may play 
an important role in the generation of ceramides in vascular endothelial cells. 
TNF-α normally causes endothelial cell activation through transcription factors 
NF-κB and -Jun/ATF-2. Studies performed on human umbilical vein endothelial 
cells showed the significance of the adaptor protein TRAF-2 for activation of both 
NF-κB and JNK [24]. In addition, JNK activation occurs via small G proteins Rac-
1 and/or cdc-42. Interestingly, TNF-α induces apoptosis when combined with 
protein synthesis inhibitor, cycloheximide (CHX) or ceramide. The apoptotic 
pathways seems to be dissimilar, because pathway induced with TNF-α + CHX is 
inhibited by the caspase inhibitors crmA or the peptide zVAD.fmk, whereas that 
induced by TNF-α + cer is blocked by the anti-apoptotic proteins Bcl-2, Bcl-XL or 
Al [24]. These data indicate a dual role of TNF-α, whereby it can act as a pro-
apoptotic agent when associated with cytotoxicity or irradiation. The mechanism 
involved in this process includes TNF-α mediated induction of nSMase, 
augmentation of ceramides and apoptosis. The adaptor protein FAN plays a key 
role in the activation of nSMase, as TNF-α is not able to generate appropriate 
level of ceramides, when FAN is underexpressed [24]. 
Action of inflammatory cytokine IL-1β is also linked with ceramide 
synthesis in many tissues. In anterior hypothalamic (AH) neurons IL-1β inhibits 
neuronal signaling by rapidly increasing the phosphorylation of the tyrosine 
kinase Src and kinase suppressor of Ras (ceramide activated protein kinase) 
4 
(CAPK/KSR), leading to activation of the neutral sphingomyelinase and 
accumulation of ceramide [25]. 
The involvement of ceramide as a second messenger in inflammatory lung 
diseases has been shown for acute lung injury and emphysema. Ceramides play 
a pathologic role in acute lung injury induced by platelet-activating factor (PAF). 
PAF-dependent pulmonary edema develops either trough the activation of the 
cyclooxygenase pathway or activation of acid sphingomyelinase with the latter 
leading to accumulation of ceramides [26]. 
Acid sphingomyelinase also has a role in the formation of ceramides 
following injection of lipopolysaccharide (LPS) or TNF-α, into C57BL/6 mice, 
which was associated with apoptosis in endothelium of intestine, lung, fat and 
thymus. Interestingly, the apoptosis was inhibited in the endothelium by 
administration of TNF-binding protein, a protective factor against LPS-induced 
cell death. That ASMase knockout mice were protected against endothelial cell 
apoptosis suggested the importance of ceramides in programmed cell death [27]. 
Vascular endothelial growth factor (VEGF) family and its receptors are 
major mediators responsible for angiogenesis and vasculogenesis [28], [29]. 
Chronic blockade of VEGFR in rats with the inhibitor SU5416 causes alveolar cell 
apoptosis and emphysema [30], a finding recapitulated in VEGFloxP mice, after 
ablation of the VEGF gene following intra-tracheal administration of an adeno-
associated cre recombinase virus (AAV/Cre) [31]. Ceramide, a second 
messenger lipid, was a critical mediator of alveolar destruction in emphysema 
caused by blockade of the vascular endothelial growth factor receptors in both 
5 
rats and mice [32]. Inhibition of enzymes controlling de novo ceramide synthesis 
prevented alveolar cell apoptosis, oxidative stress and emphysema. In a model 
of emphysema reproduced with intratracheal instillation of ceramide in naive 
mice, a feed-forward mechanism was observed, in that synthesis of ceramides 
was mediated by activation of secretory acid sphingomyelinase [32]. 
Furthermore, reduction of lung levels of very long ceramides after 
administration of a neutralizing ceramide antibody in vivo and the inability of acid 
sphingomyelinase–deficient fibroblasts to augment endogenous ceramide 
synthesis in response to exogenous ceramide also indicated a feed-forward 
mechanism of ceramide regulation mediated via the secretory acid 
sphingomyelinase [33]. 
 
1.2. Protease-antiprotease disequilibrium in emphysema 
 The concept of protease-antiprotease imbalance was the first mechanism 
involved in emphysema development. It has been shown, that emphysema 
develops when there is an overabundance of proteases with/or a decrease in 
antiproteases activity, which leads to destruction of the lung matrix. Neutrophils 
participate in the destruction of lung tissue in COPD via secretion of numerous 
proteases, such as elastase, proteinase-3, catepsins G and B [34-37] leading to 
lung tissue digestion. Macrophages can also participate in lung destruction. They 
synthesize and discharge many proteinases, including matrix metalloproteases 
(MMPs), cathepsin K, L and S [38], [23]. Interestingly, they are able to engulf and 
6 
store elastase from neutrophils for later release [39]. The antiproteases degrade 
or neutralize proteases, maintaining appropriate homeostatic balance, as 
illustrated by the action of α-1-antitrypsin, an inhibitor of neutrophil elastase [40] 
[41]. Low circulating levels of α-1-antitrypsin are associated with a panacinar type 
of emphysema development at an earlier age compared to usual emphysema 
[42]. 
 
1.3. Oxidative stress in emphysema 
 Oxidative stress can be characterized as disproportion between reactive 
oxygen species (ROS) production and capability of cells or tissues for 
neutralization of ROS via antioxidants [43]. In humans, oxidative stress has been 
implicated in the pathogenesis of many diseases, including cancer [44], 
Parkinson’s and Alzheimer’s diseases [43], atherosclerosis, myocardial infarction 
[45], and emphysema [7]. For the development of COPD and particularly 
emphysema, CS is considered the most important environmental factor. CS 
contains approximately 4,700 chemical compounds and one CS puff comprises 
1015 ROS of whose alkyl and peroxyl types are the most common [46]. CS also 
comprises many chemical particles with high redox potential, responsible for 
indirect generation of superoxide anion, peoxynitrite, alkyl peroxynitrites and 
hydrogen peroxides [47]. Moreover, CS accumulates over time in the lungs of 
smokers in the form of tar, that constitutes a permanent source of ROS 
production, especially when antioxidant mechanisms, such as GSH, Nrf2, SOD 
7 
are depleted [48], [49]. In patients with COPD, the increased influx of 
inflammatory cells, such as neutrophils and macrophages is also a prolific ROS 
source. ROS, that include H2O2, superoxide peroxynitrite, are responsible for 
many pathological issues during the course of COPD, such as suppression of 
antiproteolytic enzymes, peroxidation of membrane lipids, extracellular matrix 
remodeling and direct injury of alveolar cells, including apoptosis [46]. The 
oxidative stress participates in the generation of ceramide and is responsible for 
ceramide-induced apoptosis in human lung epithelial cells [50]. It has been 
proposed that apoptosis can be a consequence of an imbalance between 
reactive oxygen species (ROS), and antioxidants production [51]. 
 
2. Sphingolipids  
2.1. The role of sphingolipids in cell biology 
Sphingolipids are a group of lipids which have as a backbone a sphingoid 
base, an amino alcohol to which various groups are attached. They were first 
discovered in extracts from brain in the 1870s. The reason they were named 
after the mythological Sphinx was because of their enigmatic structure. 
Sphingolipids, including ceramides are important components of cellular 
membranes and their composition impact plasma and other membrane functions 
and dynamics. 
Ceramides are involved in signaling of a variety of cellular processes, 
such as apoptosis, growth arrest, and senescence [52-54] and they have been 
reported to be a second messenger of apoptosis of both lung endothelial and 
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epithelial cells in vitro. Overproduction and accumulation of ceramides are 
involved in the alterations of the lung parenchyma induced by CS, which 
culminate in the development of emphysema [55], [9]. Ceramide can be 
synthesized via several pathways, of which the most relevant are the de novo 
and sphingomyelinase pathways. Enzymes involved in the de novo ceramide 
synthesis can be activated by many environmental factors, including heat stress, 
oxidative stress and many others which collectively lead to overproduction of 
different ceramide species. An increase in ceramide production or paracrine 
action of instilled ceramides in experimental emphysema models leads to 
activation of death receptors and finally to caspase-3 activation. Petrache et al. 
previously identified ceramide as an upstream mediator of lung cell apoptosis in 
a murine model of emphysema which is induced by blockade of the vascular 
endothelial growth factor [32]. They then documented increased ceramide levels 
in response to smoking. However, the mechanism by which various 
environmental factors, including CS increases ceramide species in the lung is still 
not fully understood. Because in a simplified experimental model of emphysema 
development extensive lung apoptosis was dependent on increased in ceramides 
[32], I propose that ceramide may be an important mediator of cigarette smoke-
induced lung cell death and hence emphysema. Since ceramides are actively 
regulated by both synthetic enzymes and various degradation pathways, they 
may be targeted for therapeutic purposes to reduce CS-induced lung cell 
apoptosis. 
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2.2. Overview of sphingolipids biochemistry 
2.2.1. De novo pathway of ceramide synthesis 
2.2.1.1. Serine palmitoyl transferase  
Serine palmitoyl transferase (SPT) [EC 2.3.1.50] is responsible for the first 
committed step in the de novo ceramide synthesis pathway (Schematic 1) in all 
organisms studied to date [56]. Although its role is to combine serine and 
palmitoyl-CoA into 3-ketodihydrosphingosine (KDS), STP is able to synthetize 
alternative sphingoid bases [57] from compatible acyl-CoA [58] and amino acids 
[59]. SPT is a member of pyridoxal 5V-phosphate (PLP)-dependent α-oxoamine 
synthases (POAS) family. In mammals, SPT is represented as a heterodimer of 
53-kDa LCB1 and 63-kDa LCB2 subunits or SPT1 (SPTLC1) and SPT2 
(SPTLC2), respectively, and those subunits are localized in the endoplasmic 
reticulum (ER) with type I topology. LCB2, when dissociated from LCB1, may 
become unstable. Activity of SPT, a housekeeping enzyme, is regulated both 
transcriptionally and post-transcriptionally, and its activation may play a role in 
apoptosis induced by certain types of stresses [56]. Since both subunits appear 
crucial for embryonic development, either SPTLC1 and SPTLC2 knockout mice 
are non-viable [60]. 
SPT is expressed in normal epithelial and endothelial lung cells, but its 
subunits vary in specific cell compartments. For example, in adrenomedullary 
chromaffin cells the LCB1 subunit was found in both nucleus and cytoplasm, 
whereas LCB2 was primarily found in cytoplasm [61]. The LCB1 subunit’s 
transmembrane domain plays an essential role in upholding the LCB2 
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component and the SPT integrity in mammalian cells [62]. A recently identified 
novel SPT subunit, SPTLC3, shows about 68% identity to SPTLC2 and also 
includes a pyridoxal phosphate consensus motif. SPTLC3 subunit has a high 
affinity for myristoyl (C14: 0)-CoA and less affinity for palmitoyl (C16: 0)-CoA [63], 
thus generating C16-sphingoid bases. 
Regulation of SPT activity 
Members of ORMDL family ER transmembrane proteins are responsible 
for regulation of SPT activity. These proteins were first discovered during 
analysis of genes responsible for retinitis pigmentosa [64]. First described in 
yeast as Orm1 and Orm2, in mammals they are represented by ORMDL1, 
ORMDL2 [65] and ORMDL3, a gene recently associated with asthma 
susceptibility in humans [66]. ORMDL proteins interact and inhibit SPT activity. 
The inhibitory activity of Orm depends on the phosphorylation level of the protein 
(the higher the phosphorylation – the higher the SPT inhibition), and myriocin 
(Myr), a potent inhibitor of SPT works by phosphorylation of ORMDL proteins 
[67]. 
In yeast, a protein kinase Ypk1 seems to be an essential upstream 
regulatory factor for Orm protein family. It acts by phosphorylation specific three 
residues which are also phosphorylated by Myr. The activity level of Ypk1 kinase 
is also phosphorylation dependent and recent data indicate rapamycin complex 
kinase 2 (TORC2) as an upstream activator of Ypk1 [68]. 
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2.2.1.2. Ceramide synthases 
Ceramide synthases are enzymes that use either dihydroshingosine or 
sphingosine and specific acyl-coA as substrates [69], [70], [71] (Schematic 1). 
Discovery of the gene products Lag1p and Lac1p in yeasts and the fact that they 
were responsible for the production of C26-ceramide [72], [73], resulted in the 
report of the six paralogs of Lag1 and Lac1 in mammals, including human and 
mouse, which were named LASS (longevity assurance) genes and later CERS 
(Ceramide synthases); in all species studied to date, at least two LASS genes 
have been found in every organism. The CERS genes encode for multi-
transmembrane (TM) spanning proteins. Although neither the topology nor the 
exact number of TM domains have not been precisely yet evaluated [70], [74], 
[75], some conclusions about LASS mammalian proteins structure and function 
have been made based on studies with yeasts proteins Lag1 and Lac1. Those 
have eight TM domains, with the N and C termini of the proteins facing the 
cytoplasm [76], and one TLC domain (after Tram, Lag, CLN8) [77]. There is little 
information provided about the catalytic synthetic mechanism for LASS enzymes, 
although some data generated in yeast indicate the importance of two conserved 
histidine residues within the Lag1 motif [74], [78], [76]. Each mammalian CerS 
enzyme, with the exception of CerS1 has a Hox domain as well, which appears 
to be important for CerS5 and CerS6 activity [79]. CerS, like other enzymes of 
the de novo pathway are localized in ER [80], [81], [82], [83], [76]. All CerS 
enzymes have comparable Km to the sphinganine substrate [84], but they have 
different affinity for a particular second substrate, acyl-S-CoA. CerS1 is 
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predominantly responsible for the synthesis of C18 ceramides [82], CerS2 
synthesizes C20-C24 ceramides, CerS4 and CerS5 synthetize C18/20 and C16 
ceramides, respectively [83]. CerS6 produces C14 and C16 [81], and CerS3 
generates C18 and C24 ceramides [85]. CerS have various tissue distribution 
and expression levels. CerS1 is found in skeletal muscles and testis and is highly 
expressed in brain tissue, specifically in neurons [86], which correlates with 
elevated level of C18 ceramides. CerS2 is found in many different human 
tissues, including brain, kidney, liver and lungs [87], [88], [86]. CerS3 is mostly 
expressed in testes [89], in the skin [85], especially in keratinocytes [90], where it 
is responsible for the maintenance of water permeability barrier [91]. CerS4 is 
found in skin, leukocytes, heart and liver [88]. Moreover, CerS4 may play a role 
in development of Alzheimer’s disease, because it was found increased in the 
brain of mice with experimentally induced Alzheimer’s disease [92]. CerS5 is 
found to be in high level in the lungs [93] and brain tissue [86]. CerS6 is localized 
mostly in rapidly developing tissues including embryonic [94] and cancer tissues 
[95], [96]. Others and our lab demonstrated that in the lungs, CerS2 and CerS5 
exhibit the highest activity [88], [93], [77]. 
Regulation of ceramide synthases 
Laviad et al. proposed recently that different CerS modulate their activities 
by dimer formation within ER. This process allows not only for modulation of 
activities of different CerS isoforms, but also permits increased synthesis of 
ceramides in the de novo pathway [97]. 
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2.2.1.3. Dihydroceramide desaturases 
A product of SPT, 3-dehydrosphinganine, undergoes spontaneous 
reduction by the NADPH-dependent 3-dehydrosphinganine reductase to D-
erythrosphinganine [98], [99], [100]. For several years it was not clear whether 3-
dehydrosphinganine was first desaturated to form sphingosine and then acylated 
to yield ceramide or first acylated and then desaturated [71], [56]. The discovery 
of fumonisin B1, an inhibitor of N-acylation of sphingoid base catalyzed by a 
group of CerS brought the evidence that dihydroceramide (DHC) was an 
intermediate in sphingolipid biosynthesis and not sphingosine [56]. D-erythro-
sphinganine is first acylated and the subsequent introduction of the 4,5-double 
bond by the dihydroceramide desaturase leads to the formation of ceramide [98]. 
There are 2 isoforms of DHC desaturase. The DHC desaturase 1 (DEGS1) 
presents various affinity to its substrates which seems to rely on many factors 
such as: alkyl chain length of the sphingoid base (C18 > C12 > C8) and fatty acid 
(C8 > C18); the stereochemistry of the sphingoid base (D-erythro- > L-threo-
dihydroceramides); the nature of the headgroup, with the highest activity for 
dihydroceramide, but some (about 20%) also for dihydroglucosylceramide [98]. 
Dihydroceramide desaturase (DEGS) enzymatic action appears similar with the 
mechanism of delta 9-desaturase (stearoyl-CoA desaturase) [99], [98]. 
Oxygen is necessary for dihydroceramide desaturase activity and cyanide, 
divalent copper, as well as antibodies against cytochrome b5, and dithiothreitol 
act as inhibitors [98]. Oxydative stress inhibits activity of DEGS, leading to the 
accumulation of DHC. Interestingly, DEGS protein level during exposure to CS is 
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not changed [101]. Data from our lab indicate that DEGS is an oxygen sensor in 
minor hypoxic conditions, regulating the flow of ceramide production in the de 
novo pathway [102]. The role of DEGS2 is more enigmatic. DEGS2 is able to 
provide a desaturation of DHC; in addition it serves as hydroxylase [103]. 
 
2.2.3. Sphingomyelinase pathway of ceramide synthesis 
2.2.3.1. Sphingomyelinases 
Shingomyelinases are enzymes (EC 3.1.4.12) responsible for the 
hydrolysis of sphingomyelin to phosphocholine and ceramide [104]. 
Sphingomyelinases are classified into 3 main groups based on their optimum pH 
(acid, neutral and alkaline) and they can be additionally subcategorized based on 
their cellular compartmentalization and specific cations requirement [105]. 
Alkaline sphingomyelinase was found almost exclusively in intestinal 
mucosa of mammals, and in the human liver [106]. 
Lysosomal acid sphingomyelinase (L-ASMase) was found primarily in 
lysosomes, but it can be displaced to the outer leaflet of plasma membrane [105], 
[107]. L-ASMase was first described in 1963 as being active at acidic pH [108] 
and a deficiency of L-ASMase causes Niemann-Pick disease [109], [110]. A gene 
encoding for L-ASMase was described as Smpd1 [111]. A secreted ASMase 
isoform, first found in fetal bovine serum and localized to the outer leaflet of the 
plasma membrane, shares also the same gene [112]. Zn2+ cations are necessary 
for activity of both ASMase isoforms: lysosomal ASMase has Zn2+ firmly 
attached, whereas for secreted ASMase, Zn2+  needs to be supplemented for its 
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activity [113], [114]. The secreted form of ASMase may be responsible for 
paracrine effects leading to upregulation of ceramides at sites other than the 
source of ASMase. 
 Neutral sphingomyelinase (nSMase) has been localized to the ER and 
Golgi apparatus [105], [115] and it was found to be translocated to the inner 
leaflet of the plasma membrane [116], [115], [117]. There are three different 
types of nSMases, designated as nSM1, nSM2 and nSM3 with theirs ascribed 
genes: Smpd2, Smpd 3 and Smpd 4, respectively [118], [119], [115]. The role of 
nSM1 in cell biology still remains uncertain [120] and nSM1KO mice show no 
changes in phenotype when compared to WT animals [121]. The nSM2 is 
universally expressed and is crucial for many processes, including skeletal 
growth [122]. NSM2 has been shown to be activated in human airway epithelial 
cells in vitro by H2O2 or CS exposure [123], [124]. NSMase was found to be 
responsible for the accumulation of ceramides and apoptosis in the lungs of 
experimental animals following CS with concomitant over-expression nSM2 in 
both rodent and emphysematous human lungs [125]. Whereas hydrogen 
peroxide activates nSM2 similarly to CS, this effect is inhibited by antioxidants, 
like GSH [124]. NSM3 is a C-tail anchored membrane protein, being associated 
with both the TNF-α receptor type 1(TNFR1) and the adaptor protein FAN (factor 
associated with nSMase activation). Interestingly, its mRNA is highly expressed 
in the heart [115]. 
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Regulation of sphingomyelinases activity 
Recent data indicate that nSM2 is a phosphoprotein and its 
phosphorylation level is regulated by oxidative stress [126]. Calcineurin (CaN) 
phosphatase, known as PP2B, normally deactivates nSM2 via 
dephosphorylation. Oxidative stress causes degradation of CaN, leading to 
activation of nSM2, which when fully phosphorylated, activates downstream PKC 
and p38 MAPK [126]. There are five conserved serine phosphorylation sites on 
nSM2 and all need to be phosphorylated for full enzyme activity [125, 127]. In 
addition, aSMase in human airway epithelial cells (HAE) was found upregulated 
exclusively by peroxynitrite (ONOO−), whereas nSM was not [128]. 
 
2.2.3.2. Spingomyelin synthases 
Sphingomyelin is a major component of plasma membranes of 
eukaryotes, especially abundant in mammalian neural tissue [129] and in some 
prokaryotes [130]. Sphingomyelin synthases (SMS) are enzymes responsible for 
the synthesis of sphingomyelin from ceramide and phosphocholine, although it 
has been postulated that SMS can also provide a reverse reaction [131]. SMS 
have two histidines and one aspartic acid in catalytic domain, which are 
evolutionary stable [132]. There are 2 SMS isoforms: SMS1and SMS2. SMS1 is 
localized in the Golgi apparatus, whereas SMS2 is present both in Golgi and 
plasma membrane [133], [134]. A study suggests SMS2 is also confined to the 
nuclear membrane and chromatin [135]. In yeast, Sms1 counteracts detrimental 
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effects associated with the accumulation of ceramide, being functionally opposed 
to pro-apoptotic BAX [136] and suppression of either SMS isoforms by specific 
siRNA in mice leads to apoptosis [137]. In addition, SMS1 plays regulatory role in 
ROS generation, associated with mitochondrial function and controls insulin 
secretion [138]. 
SMS2 participates in atherosclerosis development [139], [140] via NF 
kappa B-mediated signaling process [141] and in mice with macrophages 
deficient in SMS2, the atherosclerosis progress was attenuated [142]. SMS2 may 
also be involved in controlling certain drug transporters in the brain [143]. 
Spingomyelin synthases regulation 
TNF-α, ceramide, and sphingosine are negative regulators of 
sphingomyelin synthase activity via direct mechanism [144]. IL-2 and PI-3 kinase 
are known as major positive regulatory factors of sphingomyelin synthase [145]. 
 
2.2.3. Recycling pathway of ceramide synthesis 
Ceramide is considered a central compound in sphingolipid biochemistry. 
It can serve as a substrate for the synthesis of varied sphingolipids, like 
sphingomyelins, as discussed above [139]. Ceramide phosphorylation by 
ceramide kinase (CK) leads to the synthesis of ceramide 1-phosphate (C1P) 
[146]. Ceramide can also serve as a substrate for the synthesis of more complex 
sphingolipids. In this processes glucose or galactose is added to the ceramide 
through the action of glucose or galactose ceramide synthases, respectively 
[147]. 
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In turn, the catabolism of ceramide by ceramidases [148], [149], and that 
of sphingosine-1-phosphate by sphingosine-1-phosphate phosphatases [150] 
produces sphingosine, which serves as a substrate for the synthesis of 
ceramides in a salvage pathway or is converted to S1P via the action of two 
sphingosine kinases: SK1 and SK2 [151]. In addition, S1P can be irreversibly 
metabolized to ethanolamine phosphate and hexadecenal via enzyme S1P lyase 
[152]. 
 
3. Apoptosis 
Apoptosis is a highly controlled cell death phenomenon, which is important 
for both a embryonic development and normal tissue integrity in higher 
organisms [153], [154], [155], [156], [157], [158]. There are characteristic 
histological changes during late apoptosis, like cell shrinkage, condensation of 
chromatin, and plasma membrane blebbing, which are visible by light microscopy 
[159], [160]. However, there is no inflammatory process, no leakage of cellular 
components is observed and cell content is quickly engulfed by macrophages 
with no involvement of inflammatory molecules [161], [162]. 
There are two main pathways leading to apoptosis: the extrinsic or death 
receptor pathway and the intrinsic or mitochondrial pathway, which can be 
interrelated via molecular crosstalk [163]. A third apoptotic pathway is induced 
via either granzyme B or granzyme A, and is involved in T-cell mediated 
cytotoxicity [164]. 
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The extrinsic apoptotic pathway starts with binding of specific ligands to 
their corresponding receptors on cell membrane, and the best described models 
for this type of interaction are: FasL/FasR and TNF-α /TNFR1. Following receptor 
clustering, cytoplasmic adapter proteins with death domains are recruited and 
interact with death receptors. For example, both the interaction of Fas ligand with 
Fas receptor or TNF-α with TNF-α receptor recruits adapter protein FADD or 
TRADD, along with binding of FADD and RIP, respectively [165], [166, 167]. 
Following FADD recruitment of procaspase-8, a death-inducing signaling 
complex (DISC) is created, leading to activation of caspase-8 and initiation of 
apoptosis [168]. 
The intrinsic pathway is a non-receptor mediated pathway, and is 
triggered by either negative or positive signals, leading to increased inner 
mitochondrial membrane permeability. Negative signals are described as 
deficiency of specific factors necessary for maintenance of cellular integrity, like 
growth factors, hormones and cytokines. Examples of positive signals are 
radiation, toxins, hypoxia, hyperthermia, viral infections, and free radicals [169]. 
An important step in the intrinsic apoptotic pathway is opening of the 
mitochondrial permeability transition (MPT) pore via a process called 
mitochondrial outer-membrane permeabilization (MOMP) [170]. That event 
causes liberation of two groups of pro-apoptotic proteins from the mitochondrial 
intermembrane space into the cytosol [171]. Cytochrome c, Smac/DIABLO, and 
HtrA2/Omi [172], [173], [174] are members of the first group of pro-apoptotic 
proteins, responsible for triggering the caspase-dependent mitochondrial 
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pathway. As soon as cytochrome c is released from mitochondria, it activates 
both Apaf-1 and procaspase-9. That causes the formation of more complex 
structure, called “apoptosome” and activation of caspase-9. Activated caspase-9 
is an initial signal for executioner caspases pathway, including activation of 
caspase-3 [175]. In addition, proteins Smac/DIABLO and HtrA2/Omi enhance 
apoptotic processes by blocking IAP (inhibitors of apoptosis proteins) activity 
[173], [176]. A second group of pro-apoptotic proteins discharged from 
mitochondria, include apoptosis inducing factor (AIF), endonuclease G and 
caspase-activated DNAse (CAD), which are translocated into the nucleus leading 
to DNA fragmentation [177], formation of oligonucleosomal DNA fragments [178], 
and nuclear condensation [179], [180]. CAD activation is caspase-3 dependent 
[181]. 
The intrinsic apoptotic pathway is largely controlled by proteins from Bcl-2 
family. The Bcl-2 family consists of three groups, which are not only functionally 
different, but also composed of various numbers of Bcl-2 homology domains 
(BH1-4 domains) [170]. The role of anti-apoptotic Bcl-2 proteins is to bind and 
hamper pro-apoptotic Bcl-2 proteins. The pro-apoptotic molecules comprise two 
groups. The effector group, including proteins BAK and BAX is responsible for 
formation of pores in the outer mitochondrial membrane and subsequent 
cytochrome c release [182], [183], [184]. The second group consists of the BH3-
only proteins and is responsible either for direct enhancement of BAK/BAX-
dependent MOMP (BID) [185], or hampering the activity of the anti-apoptotic 
proteins (BAD) [186], [187], [188]. The final endpoint for both extrinsic and 
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intrinsic pathways is execution phase. Caspase-3, caspase-6 and caspase-7 are 
effectors of the execution phase and responsible for many late nuclear and 
cytoplasm changes, including cleavage of proteins such as PARP and 
cytokeratins [189]. 
 
3.1. Ceramides involvement in apoptosis 
Sphingolipids act as signaling molecules, leading to multiple different 
cellular responses. In general, ceramides are pro-apoptotic, whereas S1P is a 
pro-survival molecule. Ceramides participate in development of apoptosis via 
several mechanisms. Enhancement of sASMase activity caused immediate 
ceramide production from sphingomyelin in the plasma membrane, enrichment of 
specific rafts in ceramides, which leads to the formation of death receptor 
complexes on plasma membrane, herein augmenting the extrinsic apoptotic 
pathway [190]. 
In addition, ceramides activate protein phosphatase 1 (PP1), which 
regulates the alternative splicing processes in Bcl-2 family with overproduction of 
pro-apoptotic molecules. Ceramides also activate PPA2, which, in turn, 
inactivates Bcl-2, an important anti-apoptotic protein, by dephosphorylation at 
serine 70 [191]. Thus, activation of both PP1 and PP2A turns on the intrinsic 
apoptotic pathway. Apoptosis is also triggered by ceramide via direct activation of 
cathepsin D [192]. 
Autophagy or autophagocytosis is a process leading the degradation of a 
cell's own components by lysosomes [193], [194]. This process plays a normal 
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part in cell growth and homeostasis, helping to maintain a balance between the 
syntheses, degradation, and recycling of cellular products. Autophagy can have a 
protective role, for example against oxidized low density lipoprotein (ox-LDL)-
induced injury of human umbilical vein endothelial cells [105], [115]. Autophagic 
cell death can be initiated by damaged plasma membrane, sphingolipids, and 
ceramide. For instance, exposure of human umbilical vein endothelial cells to 
glycated collagen I (GCI) causes lysosomal permeabilization followed by 
clustering of membrane rafts and it was linked to sphingomyelinase activity, 
accumulation of ceramide, clustering, and later internalization of lipid rafts [105]. 
 
3.2. Cell specific apoptosis in the lung  
Not all cells undergo apoptosis in response to ceramides. We noted an 
intracellular increase in ceramides in human lung endothelial, epithelial cells, and 
alveolar macrophages (AM) after exposure to CS (Petrusca et al., manuscript in 
preparation) [195]. Intracellular ceramides trigger apoptosis in lung endothelial 
cells [77]. However, Petrusca et al. and others noted that AM are resistant to 
ceramide-induced apoptosis [195]. This could be explained by robust activation 
of signaling pathways that promote survival of AM. Indeed, when ceramide 
production was amplified by LPS in human macrophages, the activation of PI 3-
kinase by those ceramides was observed, which led to activation of pro-survival 
pathway [196]. Some indicate also a beneficial role of ABCA1, ABCG1 
transporters, and HDL in protection and preserving viability of macrophages 
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against oxidative burst following exposure to oxidized phospholipids and/or 
apoptotic cells [197]. 
AM are responsible for the elimination of apoptotic cells in a process 
called efferocytosis [104]. Our laboratory observed that CS-dependent up-
regulation in ceramides led to an increase in number of apoptotic alveolar 
epithelial and endothelial cells in the lung with accumulation of AM. Interestingly, 
experiments from our lab showed a decrease in efferocytosis of AM in response 
to either endogenous or exogenous ceramides stimulation [195]. An inhibitory 
effect of ceramide on efferocytosis was linked to decreased membrane ruffle 
formation and impairment of Rac1 plasma membrane recruitment. This may 
imply that the upregulation of ceramides in the lungs causes both apoptosis of 
parenchymal cells and impairment of efferocytosis by AM, which collectively may 
augment lung injury [195]. 
 
3.3. Ceramide upregulation in lung endothelial cells 
Upregulation of ceramides can mediate both extrinsic and intrinsic 
pathways of apoptosis in various cell types, including endothelial cells, via 
multiple mechanisms, such as death cell receptor clustering [176] and activation 
of caspase-8 [175], direct activation of protein phosphatases 1 and 2a [15, 20, 
177], and direct effect on mitochondrial membrane permeability [198]. In addition 
to apoptosis, ceramides have been involved in endothelial oxidative stress [199-
201], growth arrest [202, 203], cytoskeletal changes [204], and senescence 
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[205]. Through these effects, ceramides regulate major aspects of lung 
endothelial cell function and, not surprisingly have been implicated in the 
pathogenesis of several conditions associated with pulmonary vascular 
dysfunction. 
Ceramides generated by the acid SMase pathway have been implicated in 
pulmonary edema induced by excessive platelet activating factor in models of 
acute lung injury or in response to surges in TNF-α that may occur following 
acute exposure to LPS in sepsis [26, 206]. The mechanism by which ceramide 
signaling leads to lung injury involves modulation of NO signaling in endothelial 
cell caveoli in a fashion that appears unique to the pulmonary circulation [207]. 
Interestingly, the pro-edemagenic effect of ceramides on the lung endothelium 
appears to be apoptosis-independent [208], the typical cellular response induced 
by excess ceramides. This dichotomy in the signaling effects of ceramides on the 
cultured lung endothelium recapitulates that of TNF-α [209] is a key inflammatory 
cytokine and a potent inducer of ceramides in endothelial cells. 
The consequences of sustained or chronic ceramide upregulation in the 
lung endothelium, induced either by direct instillation of ceramides to the lung or 
by a decrease in VEGF signaling, or by targeted endothelial mitochondrial 
damage, have been associated with increased endothelial cell apoptosis, and in 
vivo, with airspace enlargement and a phenotype consistent with lung 
emphysema [210], [211], [212]. Cigarette smoke, which is the most common 
cause of emphysema, increases ceramides in endothelial cells and in the whole 
lung animal models and in individuals who smoke or who have a diagnosis of 
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emphysema [32, 201, 213-215]. Petrache et al. demonstrated, that increased of 
lung ceramides are sufficient to cause alveolar endothelial and epithelial cell 
apoptosis, activation of macrophages and matrix proteolysis, which altogether 
recapitulate the phenotype of emphysema and that upregulation of ceramides via 
the de novo pathway of synthesis was necessary for apoptosis and airspace 
enlargement in the VEGF receptor blockade model of emphysema [32]. More 
recently, a requirement of neutral SMase-generated ceramides has been 
reported in relation to cigarette smoke-induced epithelial cell apoptosis [214]. The 
relative contribution of endothelial and epithelial cell-generated ceramides to 
apoptosis and airspace enlargement in response to cigarette smoke remains to 
be elucidated and will be addressed in my thesis. Cigarette smoke exposure may 
elevate ceramides either by oxidative stress, by VEGF receptor deprivation, or as 
recently reported, via alterations in the function of cystic fibrosis transmembrane 
regulator (CFTR), which in turn regulates ceramides at the plasma membrane 
through a process that may involve the de novo pathway [216]. Noe et al. 
demonstrated that in lung endothelial cells, CFTR was required for proper 
ceramide homeostasis through a process that involved intracellular pH regulation 
that in turn affected both the sphingomyelinase and the de novo pathway 
enzymatic function [217]. These findings complement the elegant work by 
Gulbins et al. which demonstrated the importance to ceramide-mediated effects 
on epithelial cells with mutant CFTR in models of cystic fibrosis, where acid 
SMase plays a key role in the pathogenesis of this disease, controlling rates of 
epithelial cell apoptosis and the susceptibility to chronic lung infection [218, 219]. 
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The mechanisms by which ceramides contribute to emphysema development 
involve increased oxidative stress and apoptosis, which are linked via mutual 
interaction and self-amplification [201]. In addition, de novo synthesized 
ceramides, and especially downstream production of sphingosine via acid 
ceramidase profoundly inhibit the clearance of apoptotic cells by specialized 
alveolar macrophages [220]. This is yet another self-perpetuating cycle triggered 
by ceramides, which both increases apoptosis of structural endothelial and 
epithelial cells in the lung and inhibits their clearance by macrophages, a process 
which may contribute to increased inflammation in the lungs of smokers and 
patients with COPD [221]. 
The involvement of endothelial cell ceramides in the pathogenesis of 
pulmonary vascular diseases that include pulmonary hypertension or ischemia 
reperfusion injury has not been reported, indicating a need for future 
investigations in these areas. 
Harnessing ceramide’s pro-apoptotic signaling in the endothelium could 
be achieved by inhibiting ceramide synthesis in the context of injury, or by 
counteracting its biological effect through concomitant upregulation of pro-
survival pathways, such as those initiated by S1P. Both acid and neutral SMase 
inhibitors, as well as inhibitors of the de novo pathway of ceramide synthesis 
effectively inhibited ceramide-induced apoptosis in the lung in various acute or 
chronic injury models in vivo, in which these pathways were found activated, as 
mentioned above, and recently reviewed by Uhlig and Gulbins [222]. Petrache et 
al. demonstrated that inhibition of ceramide synthesis in the context of normal 
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lung homeostasis may be detrimental, as shown in previous work with fumonisin 
B1, a ceramide synthases inhibitor, which dose-dependently increased 
endothelial cell apoptosis, lung apoptosis, and airspace enlargement in naïve 
mice [32]. Such approach may deplete cells from normally required ceramide for 
proper sphingolipid metabolism, including that of generating pro-survival 
metabolites. The role of S1P in cell survival and proliferation has long been 
recognized [171], an effect that in endothelial cells could be mediated via its 
receptors, also known as endothelial differentiation, G-protein-coupled receptors 
[223]. Diab KJ et al. proposed that, similar to other organs, a balance between 
proapoptotic ceramide and prosurvival S1P is required for maintenance of 
alveolar structures in the lung [210]. Treatment of mice with agonists of S1P1 
receptor inhibited endothelial cell apoptosis and airspace enlargement typically 
induced by VEGF receptor blockade [32], suggesting the pro-apoptotic function 
of ceramide can be antagonized by engaging S1P signaling in the lung [210]. 
In addition to cell survival, S1P modulates pulmonary endothelial cell 
motility and barrier function either intracellularly [224], or outside-in via specific 
S1P receptors, such as S1P1, which typically exerts barrier protective actions 
[225], or S1P2, which is barrier disruptive [226]. There is evidence of a complex 
interplay between signaling initiated by specific S1P receptors of the presence of 
intracellular targets of S1P or its synthetic analogs, along with a cell-specificity for 
responses to S1P [227-229]. 
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3.4. RTP801 and lung cell apoptosis 
There is ample evidence that mechanisms of amplification of lung injury 
lead to destruction of alveolar walls and persistence of inflammatory systemic 
and lung responses in COPD [8], [230]. Ceramide and RTP801 have been 
identified as potential signaling relays that are engaged early by CS exposure, 
which may interact and therefore amplify alveolar wall injury in emphysema [32, 
201, 231]. Both ceramide and RTP801 are involved in apoptosis, but it is not 
known if they are mechanistically linked. 
RTP801, also known as REDD1, is a stress response protein and 
signaling mediator stimulated by oxidative stress generated by CS and triggers 
NF-κB-mediated inflammation in the lung as well as apoptosis of alveolar 
structural cells [231]. The upregulation of RTP801 was detrimental to the lung, 
since mice lacking RTP801 were protected against CS-induced emphysema, 
concomitant with an increase in trophic factors including VEGF. The finding that 
lungs of patients with emphysema exhibit increased RTP801 expression [231] 
spurred on interest in RTP801 as a therapeutic molecular target. Mechanistic 
studies of RTP801 have been performed in the CS mouse model that 
recapitulates many aspects of the complex pathogenesis of COPD. A further 
simplified model which replicates the paucity of VEGF signaling in the lung 
parenchyma of patients with emphysema and highlights the apoptotic destruction 
of lung alveoli is obtained by inhibition of the VEGF receptors (VEGFR) [30]. In 
this murine model, apoptosis-dependent emphysema develops 4 weeks following 
a single subcutaneous injection of the VEGFR inhibitor SU5416 [30, 32]. 
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Petrache et al. measured robust upregulation of ceramide production in the lungs 
of VEGFR-inhibited rats and mice via the de novo pathway during the first week 
following SU5416 injection [32]. The time of ceramide upregulation coincided with 
increased oxidative stress and apoptosis, all preceding the onset of airspace 
enlargement [32]. However, it is not known if RTP801 is stimulated in this model, 
a question I approached in my work. 
Based on recent evidence, RTP801 may be one of the earliest stress 
responses to CS exposure that integrates oxidative stress with lung inflammation 
and apoptosis [231]. Since both ceramide and RTP801 may be central amplifiers 
of alveolar wall destruction in emphysema, we investigated if they are 
mechanistically linked and if RTP801 is one of the mechanisms by which 
ceramide induces alveolar cell apoptosis. 
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B. HYPOTHESES 
1. Cigarette smoke increases lung ceramides via activation of its synthetic 
pathways. 
2. Ceramides are necessary for cigarette smoke-induced alveolar cell 
death. 
3. Ceramide induces alveolar epithelial and/or endothelial cell apoptosis via 
RTP801 upregulation. 
 
 
 
 
 
 
 
 
 
 
 
31 
C. MATERIALS AND METHODS  
1. Chemicals and reagents 
All chemical reagents were purchased from Sigma-Aldrich (St. Louis, MO), 
unless otherwise stated. 
 2. Mouse strains  
C57BL/6 mice 6-10 weeks old females were purchased from Harlan 
(Indianapolis, IN) and housed in the Laboratory Animal Resource Center at 
Indiana University School of Medicine (Indianapolis, IN). C57Bl/6 mice were 
utilized for studies of RTP801 or ceramide C12:0 augmentation and for VEGFR 
inhibition and CS studies. 
DBA2/J2 mice 6-10 weeks old females were purchased from Jackson’s 
laboratory (Bar Harbor, ME) and were used in CS exposure experiments. 
Rtp801-null mice (C57bl/6x129SvEv) (females; at least 3 months old) 
were from Quark Pharmaceutical Inc. Wild type controls of similar genetic 
background (C57Bl/6 x 129SvEv females; at least 3 months old) were from 
Taconic, (Fremont, CA). Rtp801-null mice or wild type controls were utilized for 
studies of ceramide C16:0 augmentation. 
All animal studies were approved by the Institutional Animal Care and Use 
Committee at Indiana University (Indianapolis, IN). 
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3. Animal experiments 
3.1. Cigarette smoke exposure 
  In vivo CS exposure was performed as previously described [40]. Briefly, 
C57Bl/6 (female, age 12 weeks; n=5-10 per group), DBA/2J (male or female; age 
12-14 weeks; n=5-10 per group) or CerS2KO mice were exposed to CS 5 hours 
a day 5 days a week or to ambient air for up to 24 weeks. More specifically, mice 
were exposed to 11% mainstream and 89% side-stream smoke from reference 
cigarettes (3R4F; Tobacco Research Institute, KY) using a Teague 10E whole 
body exposure apparatus (Teague Enterprise, CA). The exposure chamber air 
was monitored for total suspended particulates (average 90 mg/m3) and carbon 
monoxide (average 350 ppm). Unless otherwise specified, mice were euthanized 
and lungs were processed as previously described (3) the day following the last 
day of CS exposure. 
 
3.2. Intra-tracheal instillation of pro-apoptotic molecules 
Indirect method 
Mice were anesthetized by brief inhalational halothane exposure, the 
tongue was gently pulled forward by forceps and the trachea instilled with 
ceramide-containing or vehicle (ethanol) containing perfluorocarbon solution 
applied at the base of the tongue via a blunt angiocatheter [232], via an indirect 
method of instillation, as previously described [32]. 
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Direct method 
After anesthesia, the trachea was exposed in aseptic conditions and either 
the compound or its vehicle was introduced directly into the trachea using a 
sterile needle. Following suture of the neck soft tissues, mice were allowed to 
recover. 
 Ceramide C12:0, Avanti (Alabaster, AL), was first solublilized in 100%, 
ethanol and then suspended in sterile perfluorocarbon (15 µl). The oxygen-
carrying properties of perfluorocarbon ensured adequate tolerance by the animal 
at these volumes, while its physical-chemical properties allowed for efficient 
distal lung delivery following intra-tracheal instillation [32, 201]. 
Ceramide C16:0 (Avanti) was administered intra-tracheally either as 
solution in ethanol or conjugated with PEG. 
Rtp801 cDNA (50 µg) was delivered intra-tracheally in 80 µl saline. 
 
3.3. Vascular endothelial growth factor receptor (VEGFR) inhibition   
The VEGFR inhibition model is an apoptosis-dependent model of 
emphysema development, and was conducted, as previously described [30]. In 
this murine model, emphysema develops 4 weeks following a single 
subcutaneous injection of the VEGFR inhibitor SU5416 Calbiochem (Gibbstown, 
NJ) [30, 32]. Mice were injected subcutaneously with SU5416 (20 mg/kg) or 
vehicle (carboxymethylcellulose). 
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3.4. Pulmonary function tests  
Mice were anesthetized with inhaled isoflurane and suspended vertically 
from their incisors. The neck was transilluminated with a fiber optic light source 
and the glottic opening was visualized with a custom-made laryngoscope blade. 
A 0.025” diameter guide wire was probed through the glottic opening, and a 20-
gauge Teflon catheter was advanced over the guide wire into the trachea. 
Following removal of the wire, the animal was mechanically ventilated with a 
rodent ventilator using room air, at a rate of 140 breaths per minute, a tidal 
volume of 0.3 ml, and 5 cm H2O of positive end-expiratory pressure. The animals 
were placed on a heated (37 ºC) pad and pulmonary function tests were then 
performed with the Flexi Vent system (Scireq, Montreal, PQ, Canada). Starting at 
FRC, the system was programmed to deliver 7 inspiratory volume steps, for a 
total volume of 1 ml, followed by 7 expiratory steps, pausing at each step for at 
least 1 second. Compliance was calculated by dividing the cumulative volume 
delivered at each step by the plateau pressure, averaging 3 pressure volumes 
loops for each mouse. At the conclusion of testing, isoflurane was discontinued, 
and the animal was allowed to emerge from anesthesia. Once spontaneous 
respiration had been resumed and reflexes had been returned, the tracheal 
cannula was removed. 
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3.5. Animal tissue preparation and analysis 
3.5.1. Broncho-alveolar lavage  
The broncho-alveolar lavage (BAL) fluid was collected by lavaging the 
lungs with 3 aliquots of 1 ml each, totaling 3 ml of Ca2+ - and Mg2+ - free PBS 
supplemented with 0.1 mM EDTA. Samples were centrifuged (5 min; 500 g; 4 
°C). Pellets were collected in 1 ml of red blood cells (RBCs) lysis buffer, left for 5 
min on ice, and then resuspended in PBS and counted, using a hemocytomether. 
Cytospin slides containing 10,000 cells each were made with total volume 350 ml 
of PBS centrifuged at 1350 rpm for 5 min and stained using a 3 step stain set 
(Richard-Allan Scientific). The slides were rinsed in water twice and allowed to 
dry, and then cover glasses were applied with mounting medium (Fisher) and 
cells were scored by a technician blinded to the identity of the experimental 
group. The acellular BAL fluid was snap-frozen in liquid N2 and stored at -80 °C 
for future analysis. 
 
3.5.2. Lung tissue harvesting 
The trachea was exposed and a blunt probe was inserted under the 
trachea to free it from the surrounding tissue. While trachea was raised, a 4 cm 
suture was pulled underneath it. Fine tipped scissors were used to cut a small “V” 
shaped incision of the anterior aspect of the trachea, just below the thyroid 
cartilage. A cannula was inserted into the trachea and was secured with a suture. 
Meanwhile, the thoracic cavity was open and the right atrium was punctured with 
a needle. In some experiments blood was collected to obtain plasma for future 
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analysis. The lungs were flushed by perfusing 20 ml of PBS through the 
pulmonary circulation via the RV. The right bronchus was exposed and ligated 
with a suture. A pre-warmed (up to 57 oC) 0.25% solution of low melting point 
agarose (10% formalin with PBS) was slowly introduced into the left lung with 
constant pressure of 20 cm H2O. The trachea was then clamped with a 
haemostatic clamp, the lungs and the heart were dissected en block, transferred 
into 50 ml conical tube, and left on ice (4 oC) for 10 min. The right lungs were 
aliquoted and snap frozen in liquid N2. Left lungs were cut with a sharp blade in a 
coronal plane into 5 pieces, transferred into a plastic fixation cassette and stored 
in 10% formalin solution with PBS, and sent to the Histology Core facility for 
paraffin embedding and sectioning (4-5 µm sections). 
 
3.5.3. Histological assessment 
3.5.3.1. Hematoxylin and eosin staining 
Tissues on slides were deparaffinized 3 times for 3 minutes each in Clear-
Rite 3 (Richard-Allan Scientific) or xylene, followed by immersing (3 times for 1 
min) in 100% Flex (Richard-Allan Scientific) and in 95% Flex (1 minute). Slides 
were then rinsed in running tap water briefly and put for 4 minutes in hot water 
(60-70 ºC) for 1 min to remove agarose residues, and then rinsed in deionized 
water. Samples were immersed in hematoxylin solution for 2 min and rinsed in 
tap water, to remove excess stain. Then slides were put into clarifier (Richard-
Allan Scientific) for 30 seconds, rinsed in tap water, immersed in Bluing Reagent 
for 1 min and rinsed in tap water for 1 min. Slides were then stained in Eosin-Y 
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for 30 sec and were immersed (3 times for 1 min) in 100% Flex, then in xylene (3 
times for 1 min each), followed by mounting of cover glasses, using mounting 
media. 
3.5.3.2. Detection of Rtp801 by immunohistochemistry 
Rtp801 IHC was performed after deparaffinization of slides and antigen 
retrieval with citrate solution (pH 6.0; 30 min). After inhibition of endogenous 
peroxidase activity by incubation in H2O2 (3% methanol; 30 min) slides were 
rinsed in TBS and blocked in goat serum (10% in TBS; 30 min). Primary antibody 
against RTP801 was applied (Proteintech; 1:200; 1 h), followed by secondary 
biotinylated goat anti-rabbit antibody (1:200; 1 h), streptavidin peroxidase (30 
min), and chromogen (DAB; 5 min). A set of sections was then counterstained 
with Mayer’s hematoxylin. 
3.5.3.3. Detection of active caspase-3 by immunohistochemistry 
Active caspase-3 IHC was performed on lung sections, as previously 
described [233]. Briefly, following deparaffinization and hydration, sections were 
blocked with goat serum (10%) and incubated with anti-caspase-3 antibody (Cell 
Signaling; 1 h at room temperature or overnight at 4 ºC). Slides were then 
stained with biotin-conjugated goat anti-rat IgG secondary antibody (1:100; 
Vector Laboratories, Burlingame, CA) and streptavidin-coupled phycoerythrin or 
fluorescein isothiocyanate (1:1,000; Vector). Sections were counterstained with 
DAPI and mounted with Mowiol 488 (Calbiochem). Microscopy was performed on 
either Nikon Eclipse (TE200S) inverted fluorescence or a combined 
confocal/multiphoton inverted system (Spectraphysics laser, BioRad 
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MRC1024MP). Images were captured in a masked fashion and quantitative data 
were obtained by Metamorph Imaging software (Molecular Devices, Sunnyvale, 
CA) as previously described [233]. 
 
3.5.4. Morphometric analysis 
Morphometric analysis was performed on coded slides as described previously, 
using a macro developed by Dr. Tuder for MetaMorph [234]. 
 
3.5.5. Apoptosis assessment by flow cytometry 
Besides apoptosis evaluation with IHC, apoptosis of specific lung cell 
populations was measured in cell suspensions isolated after lung disintegration, 
followed by the detection of cleaved caspase-3 using flow cytometry. For channel 
setup, we used Jurkat cells (Lymphoma T cells from ATCC; 106 in 100 µl) stained 
with FITC labeled anti CD3 (eBioscience) for FL1 and with Phycoerythrin (PE) 
labeled anti CD3 (eBioscience) for FL2. Cell suspensions were incubated with 
anti CD32/16 antibody (Santa Cruz Biotechnology; 1 µg/106 cells; 10 min), 
followed by washing and transfer into flow cytometry tubes. Labeling of selected 
cell populations was achieved with rat anti-mouse CD31 FITC conjugated 
antibodies (BD Pharmingen; 30 min) for the detection of endothelial cells, using 
as isotype control a rat IgG 2 FITC conjugated (eBiosciences). For the detection 
of type I pneumocytes, Alexa Fluor 488 Golden Syrian Hamster IgG anti 
Podoplanin antibody (eBiosciences) was used, with an isotype control Golden 
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Syrian Hamster IgG FITC conjugated (eBiosciences) antibody as control. Cell 
suspensions stained for alveolar type II cell markers were first prepared for 
intracellular staining. All samples underwent fixation and permeabilization with 
paraformaldehyde (1% in PBS) and Triton-X 100 (0.1% in PBS), respectively. 
Pro-surfactant C rabbit anti-mouse FITC labeled Abs were used, which were 
obtained by labeling rabbit polyclonal anti-pro-surfactant C IgG antibodies 
(Millipore/Abcam) with FITC using a kit (Pierce), following the manufacturer’s 
instructions. For isotype control, cells were stained with rabbit anti-mouse 
polyclonal IgG antibody (SouthernBiotech) which was labeled with FITC using a 
similar kit. Staining for active caspase-3 in lung cell suspensions was achieved 
by using PE conjugated affinity purified polyclonal rabbit antibody raised against 
active caspase-3 (BD Pharmingen), and an isotype PE conjugated IgG antibody 
(Southern Biotech). Following staining (30 min), samples were washed, 
centrifuged (500g; 5 min; RT) and cell pellets were suspended in BSA (1% in 
PBS) for flow cytometry analysis. 
 
3.6. Enzymatic caspase-3 activity assay 
3.6.1. Preparation of samples 
3.6.1.1. Preparation of cells: Media was discarded and cells were washed 2x in 
PBS and harvested in caspase-3 lysis buffer with fresh protease inhibitors 
cocktail (1/100), using approximately 230 µl for each well from 6-well plates. 
Cells were collected on ice (4 ºC) by scraping, transferred into Eppendorf tubes, 
and sonicated for 20 sec. Then samples were centrifuged for 10 min, 4 ºC, at 
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10,000 rpm. The supernatants were collected into clean tubes and stored at 
minus 80 °C. 
3.6.1.2. Preparation of tissue: Lung tissue (4 - 5 mm3) was homogenized with 
electric homogenizer in caspase-3 lysis buffer with fresh protease inhibitors 
cocktail 1/100, using approximately 600 µl of buffer for each sample. Then, 
samples were sonicated for 20 sec and centrifuged for 10 min, 4 ºC, at 
10,000rpm. The supernatants were collected into clean tubes and stored at -80 
°C. 
For preparation of homogenates we used the following caspase-3 lysis 
buffer: 50 mM HEPES (pH 7.4); 100 mM NaCl; 0.1% CHAPS; 1 mM DTT; 0.1 
mM EDTA. 
3.6.2. Caspase-3 activity assay 
While working on ice (4 oC), 50 µl of each sample was added into each of 
a 96 well plate in duplicates. Next, 50 µl of substrate for caspase-3, 2-DEVD-
R110 (x100) (Promega) (1/100 dilution in caspase-3 assay buffer) was added 
into each well. A 1.5 hour kinetics assay was performed using λ= 485 nm for 
excitation and λ= 538 nm for emission in a fluorometer plate reader (Promega, 
Fitchburg, WI). 
Human caspase-3 (active) recombinant protein (Chemicon International, 
25 units) was used as positive control. The negative control was caspase-3 
assay buffer: 50 mM HEPES (pH 7.4), 100 mM NaCl; 0.1% CHAPS; 1 mM DTT; 
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0.1 mM EDTA; 10% glycerol. The results of caspase-3 activity were normalized 
by the protein concentration of the sample. 
 
4. Cells culture experiments 
4.1. Cell lines used in experiments 
HLMVEC-human lung microvascular endothelial cells; Lonza, 
(Walkersville, MD); media: EBM-2 Basal Medium 500ml with EGM-2 SingleQuot 
Kit Suppl. & Growth Factors, all from Lonza. 
L2-primary rat lung epithelial cells; ATCC, (Manassas, VA), cultured in 
Hams F12 media with 10% FBS, (American Type Culture Collection, ATCC). 
RLMLEC-rat lung microvascular endothelial cells were from the University 
of South Alabama, (Mobile, AL), cultured in DMEM; Cellgro (Herndone, VA) and 
supplemented with 10% FBS and penicillin/streptomycin. 
SAEC-small airway epithelial cells (human) were from Lonza; cultured in 
SABM Basal Medium 500 ml with SAGM with SingleQuot Kit Suppl. & Growth 
Factors (Lonza). 
All cells were cultured in a humidified 37 oC, 5% CO2 incubator. 
 
4.2. Preparation of CS extract 
An aqueous CS extract was prepared from filtered research grade 
cigarettes (1R3F) from the Kentucky Tobacco Research and Development 
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Center at the University of Kentucky. A stock (100%) CS extract was prepared by 
bubbling smoke from 2 cigarettes into 20 ml of PBS at a rate of 1 cigarette per 
minute to 0.5 cm above the filter, modifying a method developed by Carp and 
Janoff (30). The extract’s pH was adjusted to 7.4, followed by filtration (0.2 µm, 
25 mm Acrodisc; Pall, Ann Arbor, MI) and used in cell culture experiments within 
20 min. A similar procedure was used to prepare the control extract, replacing 
the CS with ambient air. 
 
4.3. Preparation of treatment media  for all culture studies. 
Prior to addition to cell culture media, sphingosine-1 phosphate (S1-P) 
(Sigma) was dissolved in DMSO. D-sphingosine (Sigma) was dissolved in 
methanol. FTY-720 was dissolved in DMSO. Ceramide C16: 0 was dissolved in 
ethanol. CS extract (100%) was diluted volume: volume at the indicated 
concentrations. 
 
4.4. Whole lung disintegration 
Mice were sacrificed using isoflurane and immediately cannulated with an 
intra-tracheal catheter. Vessels on both sides of the neck were open and lungs 
were perfused via the right ventricle with PBS without calcium and magnesium 
ions, at 37 ºC. Large vessels and bronchi were discarded. The remaining lung 
tissue was placed in 60 mm tissue culture dishes, each containing disintegration 
solution and then dissected and minced into 1-2 mm diameter fragments, 
followed by immediate transfer into 50 ml conical tube. The lung tissue 
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disintegration solution contained fetal bovine serum in Dulbecco's modified Eagle 
medium (10%), DNase I, (6.5 µg/ml, Stemcell Tech, Vancouver, Canada). 
and collagenase A (12 µg/ml) ( Roche). Lung fragments were disintegrated in this 
solution (30 min; 37 ºC) until a clear cell suspension was obtained. Cell 
suspension was filtered through a cell strainer (70 µm; Fisher Scientific, Fair 
Lawn, NJ), followed by centrifugation (10 min, 300 g, 4 ºC). Cell pellets were 
resuspended in PBS followed by the addition of Geye’s solution (erythrocyte cell 
lysis buffer) and repeated centrifugation. Cell pellets were then resuspended in 
1ml of PBS with 1% FBS. All procedures in above protocol for isolation of cells 
for culture purposes were performed in sterile conditions. 
 
4.5. Isolation of lung endothelial cells  
For isolation of lung endothelial cells, we used positive selection of 
CD146+ cells from mouse using CD146 for liver sinusoidal endothelial cells 
(LSEC) MicroBeads (Miltenyi Biotec, Cambridge, MA). All procedures followed 
Miltenyi Biotec guidelines. 
4.5.1. Magnetic labeling of cells 
Following whole lung disintegration using the above protocol, the cell 
number in each sample was determined. Cells were centrifuged for 10 min, 300 
g, at 4 ºC and supernatants were discarded. Cell pellets were resuspended in 90 
µl of MACS buffer per 107 total cells and 10 µl of CD146 (LSEC) MicroBeads per 
107 cells were added. Samples were mixed well and incubated for 15 minutes at 
4 °C. Cells were washed by adding 1-2 ml of MACS buffer per 107 cells and 
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centrifuged at 300 g for 10 minutes. The supernatant was aspirated and cells 
were resuspended in 500 µl of MACS buffer up to 107 cells, followed by magnetic 
separation. 
4.5.2. Magnetic separation with MS columns 
The column was placed in the magnetic field of suitable MACS separator. 
The columns were prepared by rinsing with the 500 µl of MACS buffer. 
Previously prepared cell suspensions were applied onto the columns and flow - 
through containing unlabeled cells was collected. The columns were washed 3 
times with 500 µl of MACS buffer. Unlabeled cells were collected for efficiency 
analysis. Washing steps were performed by adding buffer aliquots only when the 
column reservoir was empty. 
The column was then removed, placed at a distance from the separator in 
a suitable collection tube. 1 ml of MACS buffer was added onto the column and 
the magnetically labeled cells were immediately flushed out by firmly pushing the 
plunger into the column. The cell suspension was saved for culture or 
experimental evaluation. 
 
4.6. Flow cytometry analysis of apoptosis using Annexin-V/PI detection kit 
4.6.1. Cells harvest 
At the end of the experiment, either SAEC or HLMVEC were washed in 
PBS (w/out Ca and Mg), trypsinized and collected in media, followed by 
centrifugation at 500 g for 5 min at RT. Next, they were washed in 500 µl of cold 
2% BSA in PBS (with Ca and Mg) and centrifuged again at 500 g for 5 min RT. 
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4.6.2. Evaluation of apoptosis 
Apoptotic and necrotic events were quantified by Annexin V/PI staining 
using an apoptosis detection kit (R&D Systems, Minneapolis, MN) the flow 
cytometry evaluation was performed with a Beckman Coulter Cytomics FC500 
cytofluorimeter (Beckman Coulter, Fullerton, CA) with CXP software. As a 
positive control UV-treated Jurkat or rat thymocytes were used. 
 
4.7. Proliferation assay 
RLMVECs were cultured overnight in 96-well plate in full DMEM medium. 
Then cells were pretreated with 2% FBS DMEM media for 1 h and treated with 
CS along with BrdU labeling solution. After appropriate time of incubation (from 6 
to 72 h) cell proliferation was measured via BrdU incorporation using Cell 
Proliferation ELISA BrdU Kit, Roche (Indianapolis, IN). 
 
5. Evaluation of lipids 
5.1. Lipids extraction 
Lung tissue was added into 2 ml methanol, homogenized, and 1 ml of 
chloroform was then added. For samples prepared for mass spectrometry 
analysis, 20 µl of 1 ng/µl Cer 17:0 standard was added. Samples were vortexed 
briefly and sonicated for about 20 sec to break down tissue/cells clumps. Then 
samples were left 2-3 h at RT or at 4 ºC overnight. Chloroform (1 ml) and 0.1 N 
HCl (1.3 ml) were added, samples were vortexed vigorously (1 min) and 
centrifuged (16 min at 2,600 g). The lower chloroform phase was transferred with 
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a Pasteur pipette into 4 ml clear glass. The solvent was evaporated under 
nitrogen stream in the heating block and the lipid film was re-dissolved in 1 ml of 
solvent (methanol: chloroform 3:1) and stored for further analysis. 
Cell lysates were prepared in 1 ml of methanol (body fluids or 
supernatants were prepared in 2 ml of methanol), and then assayed as above, 
using ratios of methanol to chloroform to water (or 0.1 N HCl) at 1:1:0.9. 
 
5.2. Lipid phosphorus (Pi) determination by optical density 
The key assumption of this experiment is that one mole of phospholipids 
contains one mole of phosphate (Pi) that is released with heat treatment in the 
presence of perchloric acid. Therefore, by measuring released (Pi) one can 
estimate the phospholipids content of the cell lysate/tissue that is proportionate to 
the total amount of the cell/tissue used. The amount of ceramides normalized by 
(Pi) is then compared among samples within the same experiment. 200 µl of the 
lipid solution (for physiological fluids) or 100 µl (for tissue) was transferred to 8 ml 
glass tube and dried out under the nitrogen stream in. Then 50 µl of 70% HClO4 
with 1% Na2MoO4*2H2O was added into each tube, which was covered with 
Teflon tape and baked in a heating block at 200 ⁰C for 40 min. While the samples 
were exposed to heat, working reagents were prepared from 2.6 ml of 1 N H2SO4 
and 6.85 ml of ddH2O. 
47 
Eight standard solutions of Pi via serial dilution using the stock standard 
(100 mM K2HPO4*3H2O with 0.01% NaN3) were prepared. The sample and 
standard tubes were cooled down to RT, followed by the addition of 0.45 ml of 
working reagents to each tube. 50 µl of ddH2O was added to the samples and 50 
µl of the standard Pi concentration to the standard tubes. The tubes were capped 
tightly, sealed with Teflon tape and boiled in a water bath for 15 min. Then they 
were cooled down to RT and 200 µl of each was transferred in duplicates in 96-
well plate for colorimetric measurement (absorbance 815 nm). 
A standard curve was prepared, subtracting the background of the 0 
nmol/50 µl standard. The Pi values in the samples were interpolated. 
 
5.3. Ceramide quantification  
The sphingolipids were ionized via electrospray ionization (ESI) with 
detection via multiple reactions monitoring (MRM) by our collaborator, Dr. Walter 
Hubbard. Analyses of the sphingolipids were performed by combined liquid 
chromatography/ tandem mass spectrometry (LC/MS/MS). The instrumentation 
employed was an API4000 Q-trap hybrid triple quadrupole linear ion-trap mass 
spectrometer (Applied Biosystems, Foster City, CA) equipped with a 
turboionspray ionization source interfaced with an automated Agilent 1100 series 
liquid chromatograph and autosampler (Agilent Technologies, Wilmington, DE) 
[235], [236]. S1P and DHS1P were quantified as bis-acetylated derivatives with 
C17-S1P as the internal standard employing reverse-phase HPLC separation, 
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negative ion ESI, and MRM analysis. Details of this approach are described in 
[236, 237]. 
 
6. Enzymatic activity assays 
6.1. Serine-palmitoyl transferase assay 
Lungs were homogenized in SPT lysis buffer, containing 10 mM HEPES 
(pH 7.5 in NaOH); 250 mM Sucrose; 1 mM EDTA; proteinase inhibitor cocktail in 
ddH2O. An equal volume (100 µl) of each sample was used in 100 µl of SPT 
assay buffer, containing 0.1 M HEPES (pH 8.3); 2.5 mM EDTA; 50 µM pyridoxal 
phosphate; 5 mM DTT; 1 mM L-serine, prepared in ddH2O. SPT activity was 
determined by measuring the incorporation of (3H) L-serine (American 
Radiolabeled Chemicals, Inc., St. Louis, MO) into palmitoyl-CoA and expressed 
as a number of counts per minute, measured using a scintillation plate reader. 
The results were normalized by protein concentration. A boiled tissue sample 
was used as a negative control. 
 
6.2. Ceramide synthase-2 and -5 (CerS2 and CerS5) assays 
Cells or lung tissue were homogenized in ceramide synthase lysis buffer: 
5 mM EGTA; 25 mM Hepes pH 7.4; 50 mM NaF; 1 µg/ml Leupeptin; 10 µg/ml 
Soybean trypsin inhibitor in ddH2O. First, D-erythro-sphinganine (C16 
dihydrosphingosine, Avanti) was added to each glass tube and dried under N2. 
Next, it was resuspended in assay buffer, containing 2 mM MgCl2; 20 mM Hepes; 
0.5 mM DTT; 20 mM defatted BSA. For CerS 2 activity assay, “cold’ behenyl-
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CoA with radioactive 14C behenyl-CoA was utilized. For CerS 5 activity assay, 
“cold” palmitoyl-CoA, and 14C palmitoyl-CoA (American Radiolabeled Chemicals) 
were used. After 1 hour incubation at 37 oC, samples were dried out under N2, 
resuspended in 20 µl chloroform and methanol (1:1) containing 1 mg/ml bovine 
brain ceramide and 1 mg/ml diacylglycerol, and 15 ml of this mixture was loaded 
onto silica TLC plates. Liquid chromatography was performed in TLC solvent, 
containing chloroform, methanol and 3.5 N aqueous ammonium hydroxide in a 
ratio 85:15:1, respectively. Particular bands on silica plate were captured by 
Phosphoimager. Activities of ceramide synthases were calculated by 
densitometric analysis and normalized by the protein concentration of the 
homogenate. 
 
6.3. Sphingomyelinase activity assays 
The activities of specific sphingomyelinase isoforms were evaluated with 
Amplex Red Sphingomyelinase Assay Kit (Molecular Probes, Eugene, OR), 
following manufacturers protocol. Tissues were homogenized in lysis buffers 
specific for each isoform [238]. For lysosomal ASM, we used cell lysis buffer, 
composed of: 0.2% TritonX-100; 100 mM sodium acetate (pH 5.0); 2 mM EDTA; 
0.1 mM Na3VO4 (fresh); 1 mM PMSF (fresh); 10 µl/ml aprotinin (fresh); 10 µl/ml 
leupeptin (fresh), adjusted to 10 ml of ddH2O; for secreted acid 
sphingomyelinase: 0.2% TritonX-100; 100 mM sodium acetate (pH 5.0); 0.1 mM 
Na3VO4 (fresh); 1 mM PMSF (fresh); 10 µl/ml aprotinin (fresh); 10 µl/ml leupeptin 
(fresh), adjusted to 10 ml of ddH2O; and for neutral sphingomyelinase cell lysis 
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buffer: 0.2% TritonX-100; 20 mM Hepes, pH 7.4; 2 mM EDTA; 10 mM MgCl2; 5 
mM DTT (added fresh); 10 mM Beta-glycerophosphate; 0.75 mM ATP (fresh); 
0.1 mM Na3VO4;10 µl/ml Aprotinin (fresh); 10 µl/ml Leupeptin (fresh), adjusted to 
10 ml of ddH2O. The kinetics for both acid and neutral sphingomyelinases was 
measured using a fluorescence microplate reader. Hydrogen peroxide and 
purified neutral sphingomyelinase were used as positive controls. The enzyme 
activity results were expressed normalized to protein concentration. 
 
7. Evaluation of protein concentration 
Protein concentration was evaluated using BCA Protein Assay Kit (Pierce).  
 
8. Western blotting 
Detection of Rtp801. Lung tissue or cells were homogenized in a lysis 
buffer containing 20 mM HEPES, (pH 7.5), 1.5 mM MgCl2, 150 mM NaCl, 10% 
glycerol, 1% Triton X-100, 2 mM EDTA, 2 mM Na3VO4, 50 mM NaF, 1 mM 
PMSF, and protease inhibitor cocktail Set I (Calbiochem). Protein lysates were 
run on SDS- PAGE and transferred to nitrocellulose membrane, using the 
Criterion system (Biorad). The membranes were blocked with Superblock 
blocking buffer (Pierce Biotech) and incubated with indicated primary antibodies 
overnight (rabbit anti-mouse Rtp801, Quark Pharmaceuticals Inc.), and with 
secondary antibodies conjugated with horseradish peroxidase (Vector). The blots 
were developed using enhanced chemiluminescence kit (GE Healthcare). 
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9. Additional buffers and media 
PBS w/Ca,Mg: 0.1 g of CaCl2 (anhydrous), 0.1 g of MgCl2-6H20, 0.2 g of KCl, 
0.2 g of KH2PO4, 8 g of NaCl, 2.1 g of Na2HPO4-7H2O in 1000 mL of ddH2O (pH 
7.4). 
PBS w no Ca,Mg: 8 g NaCl, 0.2 g KCl. 1.44 g of Na2HPO4 and 0.24 g of 
KH2PO4 in 1000 ml of ddH2O water (pH 7.4). 
Geye’s Lysis Solution (Red cell lysis buffer); Solution A: In a 1 L beaker, 
17.5 g of NH4Cl, 0.925 g of KCl, 0.225 g of Na2HPO4 (anhydrous), 0.055 g of 
KH2PO4, 0.25 g of glucose were added to nearly 500 ml of ddH20, adjusted to a 
final volume of 0.5 L and then the buffer was filter-sterilized; Solution B: In a 0.5 
L beaker, 1.05 g of MgCl2*6H2O, 0.36 g of MgSO4*7H2O, 0.85 g of CaCl2 were 
added to nearly 250 ml of ddH20, adjusted to a final volume of 250 ml and then 
the buffer was autoclaved; Solution C: In a 0.5 L beaker, 5.625 g of NaHCO3 
was added and adjusted to 250 ml with ddH2O and then was autoclaved. 
Geye’s Solution was then constituted by adding: 10 ml Solution A, 2.5 ml 
Solution B, 2.5 ml Solution C and 35 ml dH2O. To lyse RBC, 12 to 13 ml Geye’s 
solution was added and incubated for 5 min at +4 oC. 
 
10. Statistical analysis was performed with Sigma Stat (Systat Software Inc, 
Chicago, IL), using unpaired Student t-test, ANOVA, or Kruskal-Wallis One Way 
Analysis of Variance on ranks, as appropriate. Statistical significance was 
accepted at p<0.05. 
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D.RESULTS 
1. Cigarette smoke (CS) exposure effect on lung cells ceramides and 
apoptosis in vitro and in vivo 
1.1. Lung epithelial and endothelial cells upregulate ceramides and 
undergo apoptosis in response to CS 
1.1.1. CS exposure inhibits cell proliferation in vitro 
Chronic CS exposure of decades leads to lung emphysema in susceptible 
individuals. In mice, emphysematous changes are observed as early as after 4-6 
months after CS, depending on the strain. Both lung epithelial and endothelial 
cells have been shown to undergo apoptosis in emphysema models. To 
investigate the role of ceramide in CS-induced apoptosis, I first studied the ability 
of a soluble cigarette smoke extract (CSE) to affect primary lung alveolar cell 
function. Prior to the onset of programmed cell death due to CS, there are many 
changes in cellular physiology, including inhibition of cell proliferation. I asked if 
CSE affects proliferation of endothelial cells, using rat lung microvascular 
endothelial cells (RLMVECs) as an experimental model. First, I wanted to 
determine the CSE concentration that inhibits cell proliferation of RLMVECs. I 
exposed RLMVECs for 48 h to 1, 1.5, and 2.5% CSE concentrations and 
measured proliferation by BrdU incorporation using Cell Proliferation ELISA BrdU 
Kit. I found a significant inhibition of RLMVECs proliferation at 2.5 % CSE (Figure 
1A), which is considered typically a low CSE concentration, as cell death is 
usually noted only with 5-10% CSE in these cells. Then, I used 2.5% CSE in 
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order to determine how cell proliferation is affected in RLMVECs during different 
time points of CSE. I exposed RLMVECs to CSE (2.5%) for 6, 24, and 72 hrs. 
There was a statistically significant inhibition of proliferation in all CSE treated 
cells when compared to air control (AC) extract (Figure 1B). These data indicated 
that even low CSE concentrations inhibit cell proliferation in RLMVECs, and even 
helped select CSE concentration and timepoints for our next experiment. 
1.1.2. CS exposure causes lung cell apoptosis in vitro 
To test whether CS causes apoptosis in a relevant in vitro model, I 
exposed human lung endothelial or human lung epithelial cells to increasing CSE 
concentrations (from 0.1 to 10%) for 6 h. I used commercially available human 
lung microvascular endothelial cells (HLMVEC) and small airway epithelial cells 
(SAEC), which are primary cells harvested from human lungs. After CSE 
exposure, cells were harvested and analyzed for apoptosis. Apoptotic events 
were quantified by Annexin-V/PI staining, using the Apoptosis detection kit (R&D 
Systems) and flow cytometry. In HLMVEC, there was increase in apoptosis when 
exposed to 5% and 10% CSE, which was dose-dependent (Figure 2A). In SAEC, 
I observed a similar response, albeit more robust and with less variability (Figure 
2B). These data may suggest that SAECs are more sensitive to CSE than 
HLMVEC and both cell types undergo apoptosis in response to increasing CSE 
concentration. 
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1.1.3. CS exposure increases lung cell ceramides content in vitro 
Since ceramide upregulation causes cell apoptosis, I investigated if 
human alveolar cells in culture upregulate ceramide in response to CS. Both 
SAEC and HLMVEC were exposed to increasing CSE concentrations, 
specifically from 0.1 to 10% of CSE for 24 hours. Cells were harvested and 
analysed for total ceramide content. I found increased ceramides in a dose-
dependent manner in both SAECs and HLMVECs following CSE treatment 
(Figure 3). Interestingly, the ceramide content in HLMVEC was higher than that 
in epithelial cells both at baseline and following CSE treatment. That might be 
attributed to a known large pool of acid sphingomyelinase in the endothelium 
[239]. These data show that CSE leads to the accumulation of ceramides in both 
lung epithelial and endothelial cells, and the rate and pathway of ceramide 
accumulation may determine apoptosis outcomes. 
1.1.4. CS upregulates enzymes responsible for ceramide synthesis in vitro 
If CS-induced apoptosis is due to the overproduction of ceramide, I should 
observe an increase in enzymatic activities responsible for ceramide synthesis 
after CSE treatment. Since endothelial cells are highly abundant in ASMase, I 
next determined if their activities are triggered by CS in human primary lung 
endothelial cells (HLMVEC) exposed to 5% or 10% CSE for 1, 4 and 24 h.  
There was a trend for lysosomal ASMase activation, by both moderate and high 
CSE concentrations (Figure 4A), while the secretory ASMase was significantly 
and robustly activated at 24 h (Figure 4B). In contrast, HLMVEC did not activate 
nSMase in these conditions (Figure 4C). 
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CSE of rat lung epithelial cells (L2) triggered activation of both the de novo and 
the sphingomyelinase pathways. In lung epithelial cells, exposure to moderate 
CSE concentration (5%) elicited significant activation of SPT (Figure 5A) at 4 h, 
with brief but not significant elevations of CerS5 and CerS2 activities (Figure 4b). 
By 24 h of exposure, both CerS (Figure 5B and 5C) and lysosomal ASMase 
(Figure 6A) were actually inhibited by CS. Higher concentration of CSE (10%) 
also activated SPT even earlier (at 1 h) (Figure 5A), having a positive early (4 h) 
increase in CerS5 and CerS2 activities (Figure 5B, 5C), without reaching 
significance. ASMase was also activated by high CSE concentrations in a 
sustained manner (Figure 6A and B). No change in activity was observed for 
nSM during these conditions (Figure 6C). These data show that CS activates 
ceramide enzymatic pathways in both epithelial and endothelial lung cells with 
different kinetics and amplitudes, having in epithelial cells robust activation of 
SPT and exhibiting increase of ASMase activity in endothelial cells. 
 
 1.2. CS exposure in vivo increases lung ceramides 
1.2.1. CS exposure increases total lung ceramides and DHC 
Chronic CS is associated with alveolar cell apoptosis and causes 
emphysema in susceptible individuals after decades of exposure. In mouse 
models, airspace enlargement develops after 4-6 months of CS exposure and 
apoptosis is detected as early as 1-4 weeks of exposure. To address my 
hypothesis that ceramide is involved in CS- induced apoptosis, I first measured 
ceramide following 1 or 4 weeks of CS exposure, in C57Bl/6 mice. Lung tissue 
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was harvested, ceramide and DHC levels were evaluated by LC-MS/MS and 
normalized to lipid phosphorus content. I observed increased levels of ceramide 
in the whole murine lungs at 4 weeks of CS, compared to mice of similar age 
exposed to ambient air or to those exposured to CS for only 1 week (Figure 7A). 
Interestingly, DHC, the ceramide precursor in the de novo pathway , was also 
upregulated after 4 weeks of CS (Figure 7B). these data are in concordance to 
previous studies in our lab, showing increase ceramide levels in DBA2/J mice 
exposed to CS at 4 weeks [210], and an increase ceramide levels in smokers 
lungs in humans [32], [102]. 
 
1.2.2. CS exposure activates the nSMase in vivo in both endothelial and 
epithelial type I cells 
Since cells in culture may behave differently than in situ, I investigated if 
ceramide synthetic pathways are activated in lung endothelial and epithelial cells 
type I in vivo, I exposed DBA2/J mice to CS for 1 week. Following CS exposure, 
lungs were immediately harvested, enzymatically disintegrated and sorted for the 
collection of both endothelial cells and epithelial type I cells using a Miltenyi 
Biotec system (Figure 8A). I used specific antibodies with iron microbeads and 
positive selection process. Podoplanin-specific Abs and CD146-specific 
antibodies were used for isolation of epithelial type I and endothelial cells, 
respectively. I then determined the activities of lysosomal ASMase, nSMase, and 
caspase-3 activities in both endothelial cells (Figure 8B, C and D) and epithelial 
57 
cells type I (Figure 8E and F). Of all enzymes investigated, I found a significant 
increase in nSMase in both cell types (Figure 8C and 8E). Only in epithelial type I 
cells I found a significant increase in caspase-3 activity, which indicates 
increased apoptosis in these types of cells following in vivo CSE for this short 
time (Figure 8F). 
 
1.2.3. CS exposure rapidly activates the SMase pathway of Cer synthesis in 
the whole lung 
SMases are known to be highly activated by stress, but their activities may 
be short-lived. I investigated if; unlike in the chronic model of CS exposure when 
mice are allowed to recover from CSE before harvest, immediately following 
CSE, lungs may show activation of sphingomyelinases. DBA2/J mice were 
exposed to CS for 0.5, 1, 2, and 5 hours (Figure 9A). Lung tissue was harvested 
immediately following CS and activities of sphingomyelinases were determined.  I 
found a significant increase in the activities of both acid sphingomyelinase 
isoforms: lysosomal and secreted after 1 hour following CS, with return to 
baseline after 5 hours (Figure 9B). In a separate experiment, I noted that both 
ASMase and nSMase are activated as early as 30 min following CSE (Figure 
9C). This indicates acute activation of lung sphingomyelinases during CSE. In 
contrast, the activity of CerS5, which is responsible for the synthesis of ceramide 
C16: 0, one of the most abundant lung ceramide, showed a trend for decreased 
activity after 1 hour of CS (Figure 9D). 
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1.2.4. Chronic CS activates the de novo pathway of ceramide synthesis in 
the whole lung  
Given that the upregulation of DHC suggested the activation of de novo 
ceramide synthesis, I measured the activities of enzymes in this pathway. SPT is 
the first enzyme responsible for the committed step in the de novo ceramide 
synthesis. I determined SPT activities in the whole lung tissue following 1, 2, and 
4 months of CS (Figure10). After an initial decrease after 1 month, SPT activity 
significantly increased later, at 4 months of CS exposure (Figure 10). These data 
provide evidence of upregulation of the de novo pathway following chronic CS 
exposure in DBA2/J mice. 
I next evaluated CerSs in response to CS. There are six CerS, responsible 
for synthesis of different Cer species. It is not known about the abundance of 
specific CerS in the lung. Previous work indicated that CerS5 is abundant in lung 
epithelial cells [32]. 
In collaboration with Dr. Futerman, our lab studied the relative expression 
levels of all CerS in the C57Bl/6 lung during CS exposure. They measured CerS 
expression using real time PCR of mouse lung homogenates. CerS2 and CerS5 
were the most abundant CerS in the lung (Figure11). In response to CS, CerS2 
mRNA expression was elevated late, after 6 months of CS (Figure11). 
Interestingly, the mRNA levels of one of the most abundant isoform, CerS5 
decreased starting at 1 week of CS, with return towards baseline after 6 months 
of CS (Figure11). The mRNA levels of both CerS1 and CerS4 showed a steady 
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decrease with time of CS. The only CerS, that exhibited an early upregulation in 
the expression of mRNA level, was CerS3, which increased after 1week of CS 
(Figure 10), but the low abundance of transcripts makes the significance of this 
increase unclear. In the C57Bl/6 mice, the mRNA levels for CerS2 was preceded 
by increased activity of CerS2 after 2 months of exposure (Figure12A), while 
CerS5 activity was upregulated at 2 months of CS (Figure11B), followed by 
return to (Figure 12A and B) or even below baseline activity in the C57Bl/6 
(Figure12C) late in the course of CS. 
Interestingly, there were no changes in the enzymatic activity of 
sphingomyelinases after prolonged CS, compared to control lungs (Figure 13A, 
B, C). Of note, lungs were harvested 16-24 hours following removal from active 
CS exposure. This data suggest that the de novo pathway is activated by chronic 
CS (2-4months), in particular SPT and CerS2. 
 
2. Effect of inhibition of enzymes responsible for ceramide synthesis on 
lung apoptosis following CS 
My hypothesis is that ceramide are necessary for CS-induced alveolar cell 
apoptosis. It has been shown previously that accumulation of ceramides was 
associated with VEGF blockage model of emphysema development and that 
direct instillation of ceramides led to extensive apoptosis of lung parenchyma 
[32]. If my hypothesis is true, downregulation of ceramide production will 
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decrease apoptosis. That could be achieved by using various inhibitors of 
enzymes responsible for ceramide synthesis. 
 
2.1. Effect of inhibition of ASMases on CS-induced lung apoptosis 
I first tested the effectiveness of amytryptiline (Amy), a known inhibitor of 
ASMases to prevent the activation of ASMase after acute CS exposure. I 
compared the effectiveness intra-peritoneal (i. p.) or intra-tracheal (i. t.) 
administration of Amy on the inhibition of lung ASMase (Figure14A). The i.p. 
administration of Amy significantly inhibited the activities of both lysosomal and 
secreted isoforms of ASMase in the lung following 1h CS exposure (Figure 14B 
and C). I therefore administered Amy i.p. in a chronic model of CS exposure in 
DBA2/J mice to test if the acute activation of ASMase is important for lung 
apoptosis after chronic CS exposure. Mice were exposed to CS smoke for four 
months and one group was injected with Amy for the first 2 consecutive months, 
as an early intervention (Figure 15A). Another group was injected with Amy for 
only the last two months of CS exposure, concomitant with CS exposure, as a 
late intervention (Figure 15A). After 4 months lungs from animals were harvested 
and alveolar tissue apoptosis was determined by IHC. 
There was a significant increase in caspase-3-expressing cells in the lung 
parenchyma of mice from CS group vs. AC group. There was a significant 
decrease in active caspase-3-expressing cells in the lungs of mice from early 
Amy treatment group exposed to CS (Figure 15B), compared to untreated CS-
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exposed mice (Figure 15B). These early inhibition of ASMase was not as 
effective at inhibition apoptosis at 4 months of CS. These data suggest that 
inhibition of ASMase late in the course of CS inhibits CS-induced apoptosis. 
 
2.2. Effect of inhibition of SPT on lung apoptosis due to CS 
SPT is the first enzyme in the de novo pathway of ceramide synthesis, 
and because I observed previously an increase in SPT activity in DBA2/J mice 
after 2 months of CS I asked if administration of myriocin (Myr), a potent inhibitor 
of SPT, would decrease CS-induced apoptosis. I exposed DBA2/J mice to either 
CS or ambient air for 2 months and appropriate groups were concomitantly 
administered with Myr (Figure 16A). After two months, lung tissue was harvested 
and analyzed. As expected, Myr downregulated the SPT activity in response to 
both CS and at baseline (Figure 16B). Treatment with myriocin did not 
significantly affect ASMase activity at 2 months of CS exposure (data not shown). 
However, nSMase was found significantly activated in the myriocin-treated group 
(Figure 16C), suggesting a compensatory feedback. Myriocin-treated mice had a 
significant decrease in caspase-3 activity of the whole lung, when compared to 
untreated CS exposed mice (Figure 16D). However, I could not detect any 
difference in caspase-3 activity in the whole lung after 2 months between CS and 
air control groups. (Figure 16D). I therefore evaluated lung parenchyma-only 
apoptosis, using IHC for active caspase-3. Indeed, there was increase in active 
caspase-3-expressing lung cells in alveolar tissue of CS-exposed mice (Figure 
62 
16E). Unexpectedly, Myr treatment actually increased the number of cells 
expressing active caspase-3 in CS exposed animals (Figure 16E). These data 
suggest that inhibition of ASMase was more effective at reducing lung 
parenchyma apoptosis following CS exposure than inhibition of SPT. 
 
3. Role of RTP801 on ceramide-induced lung cell-specific death 
3.1. RTP801 is upregulated in the lung ceramide-dependent model of 
emphysema 
I asked if RTP801 is involved in the mechanism of ceramide-induced 
apoptosis. As a first step in elucidating the crosstalk between RTP801, ceramide, 
and apoptosis, it was documented by the Petrache lab, that the oxidative stress-
responsive RTP801 was upregulated in the lungs during the first 7 days following 
VEGFR inhibition (Figure 17A). In this model, ceramide is upregulated and 
causes apoptosis. Interestingly, treatment of mice with the ceramide synthesis 
inhibitor FB1 inhibited the VEGFR-inhibitor-induced RTP801 protein expression, 
suggesting ceramide synthesis may be upstream of RTP801 upregulation in this 
model (Figure 17A). These data, together with previous work on RTP801 as a 
stress response molecule in the CS model of emphysema [32] indicated a 
possible interrelation between RTP801 and ceramide expression in the lung. To 
investigate if induction of RTP801 expression can increase ceramide levels, the 
Petrache lab in collaboration with Dr. Tuder and Dr. Feinstein, overexpressed 
RTP801 in the lung. 
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3.2. Rtp801 is sufficient to trigger lung apoptosis, airspace enlargement, 
and to increase lung ceramides 
I measured outcomes of another experiment, that overexpressed RTP801 
cDNA (50µg) or empty plasmid via intra-tracheal instillation [240]. At day 3 
following administration, when compared to control mice that received empty 
plasmid, the lungs of mice instilled with RTP801-expressing plasmid exhibited 
increased RTP801 protein (Figure 17B), and increased active caspase-3 as 
measured by IHC (Figure 17C). In RTP801-instilled mice, I measured an 
increased number of enlarged alveoli (Figure 17D). Interestingly, there was a 
marked increase in lung ceramides in response to RTP801 instillation, which was 
prevented by pretreatment with the ceramide synthase inhibitor FB1 (Figure 1E). 
These results suggested that VEGFR inhibition can increase RTP801 in a 
ceramide-dependent manner while, conversely, upregulated RTP801 suffices to 
trigger ceramide synthesis. 
 
3.3. Direct augmentation of ceramides in the lung increases endogenous 
ceramides and causes apoptosis, airspace enlargement, and RTP801 
upregulation 
It was previously demonstrated that a single intra-tracheal instillation of 
ceramides with a 12-carbon fatty acid side chain (C12:0; 1 mg/kg) administered 
with perfluorocarbon vehicle [32], caused overproduction of endogenous 
ceramides and lung cell apoptosis at 24h and 48h associated with an increase in 
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alveolar size [32, 201]. To further characterize the lung changes induced by 
ceramide, I instilled mice intra-tracheally with ceramide (C12:0; 1 mg/kg) or a 
with control vehicle (sham) and compared them with untreated mice. To 
distinguish exogenous from endogenous ceramides, I used tandem mass 
spectrometry to identify and measure only endogenous sphingolipids with longer 
than 14-carbon fatty acid chain. Since ceramide is the precursor of sphingosine-1 
phosphate, an important pro-survival sphingolipid, in collaboration with Dr. 
Berdyshev, I measured the ratio of ceramide to sphingosine-1 phosphate in the 
lungs following C12:0 ceramide instillation, as a better reflection of a pro-
apoptotic sphingolipid imbalance. The endogenous lung ceramide/S1P ratio 
increased at 4 h and was highest at 24 h after ceramide instillation, followed by a 
return to sham levels at 48 h (Figure 18A). Ceramide induced activation of 
executioner caspases-3/7 after 4 h, which persisted for 48 h following instillation 
(Figure 18B and C). As expected, ceramide instillation decreased alveolar 
surface area/lung volume, which became significant at 48 h (Figure 18D). To 
determine if ceramide increases are sufficient to elevate RTP801 expression in 
the lung, I next administered via a similar protocol of intra-tracheal instillation as 
C12:0 ceramide a more common endogenous ceramides, C16:0 ceramide, using 
this time polyethylene glycol conjugation to achieve improved solubilization of 
this more hydrophobic molecule. Compared to sham-instilled mice, the lungs of 
mice in which C16:0 was augmented had a 2-fold increase in RTP801 
expression in the lung parenchyma (Figure 18E and F). These results suggest a 
mutual interaction of ceramide and RTP801 induction in the lung. 
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3.4. Rtp801-null mice are protected from ceramide-induced epithelial cell 
apoptosis and emphysema-like disease 
I next asked if RTP801 induction was necessary for the pathogenic effects 
of ceramide in the lung. I instilled ceramide C16:0 intra-tracheally in the lungs of 
Rtp801-null mice, which were previously characterized in detail [231]. Compared 
to wild type mice, RTP801-deficient mice had significantly less caspase-3/7 
activity in whole lung tissue homogenates following ceramide augmentation 
(Figure 19A). Because of differential susceptibility of distinct lung alveolar cells 
types to ceramide in vivo is not known, I evaluated caspase-3/7 activation in 
specific alveolar structural cell types isolated from the lung at 48 h following 
ceramide instillation. I enzymatically disintegrated lungs and investigated the 
vulnerability to apoptosis of lung endothelial, epithelial type I, and epithelial type 
II cells in both Rtp801 KO and WT mice. Alveolar cell-type markers (CD31, 
podoplanin, and prosurfactant-C, respectively) and active caspase-3 were 
detected using labeling with specific antibodies followed by flow cytometry. 
Ceramide instillation significantly increased apoptosis in both lung endothelial 
and epithelial type II cells in wild type mice (Figure 19B). Interestingly, in Rtp801-
null mice only type II pneumocytes were protected against ceramide-induced 
apoptosis (Figure 19B). Given that RTP801 is largely upregulated in type II cells 
(but not in endothelial cells) after exposure to cigarette smoke in vivo [231], these 
findings concordantly demonstrate that RTP801 is necessary for ceramide to 
activate caspase-3 in alveolar type II epithelial cells. 
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To determine if other features of emphysema-like disease induced by 
ceramide are impacted by RTP801, we measured lung inflammation by counting 
inflammatory cells in the bronchoalveolar lavage fluid of mice. There was a 
relative increase in the polymorphonuclear (PMN) cells following ceramide 
instillation in wild type mice, which was significantly reduced in the rtp801-null 
mice (Figure 19C). As expected, alveolar macrophages exhibited reciprocal 
changes (Figure 19D). 
To measure the effect of ceramide 16:0 and the role of RTP801 on lung 
parenchyma morphology and function, following lung function testing, the left 
lung was inflated under constant pressure and airspace size was determined by 
morphometry. Compared to wild type mice, where ceramide augmentation 
increased airspace size measured by mean linear intercepts (MLI) from 37.1 to 
39.1 µm (p=0.02), in rtp801-null mice ceramide had a negligible effect on 
changes in MLI from 36.5 to 37.8 µm (p=0.3), suggesting that the lack of RTP801 
was protective against ceramide-induced apoptosis (Figure 20A and B). 
Similarly, wild type mice exhibited significant increases in the lung static 
compliance (p=0.01) in response to ceramide instillation, whereas rtp801-null 
mice did not (Figure 20C). Interestingly, ceramide instillation also elevated the 
airflow resistance in mice and this, similar to the increase of airspace size was 
more pronounced in wild type than in rtp801-null mice (Figure 20D). These data 
show that ceramide induces a COPD-like physiological phenotype, which is 
ameliorated by absence of RTP801. 
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E.DISCUSSION 
1. Cigarette smoke (CS) exposure increases ceramides both in vitro and in 
vivo, which leads to lung cell apoptosis 
1.1. Lung epithelial and endothelial cells increase ceramide levels in 
response to CSE, which leads to a programmed cell death 
1.1.1. CS exposure inhibits cell proliferation in vitro 
I showed inhibition of proliferation in RLMVEC when exposed to even low 
CSE concentration. This response allowed me to select CSE concentration 
parameters for subsequent studies. It is not known, how CSE inhibits cell 
proliferation. Excess of cellular ceramides has known pro-apoptotic effect, but 
basal levels of ceramides are necessary for cell viability, because ceramides 
serve as intermediaries for synthesis of other sphingolipids, including those with 
pro-survival and pro-proliferative role, like S1P. It is possible that the reduction in 
cell proliferation in CS exposed cells is due to either increase of DHC, increase 
ceramide to S1P ratio, or molecular changes unrelated to ceramide. 
 
1.1.2. Lung alveolar cells exhibit an increase in apoptosis in response to 
CS 
Both human lung endothelial and epithelial cells exhibited increased 
apoptosis in response to CSE, in a dose dependent manner. SAEC had a more 
consistent apoptotic response than HLMVEC when exposed to similar 
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concentrations of CS. There was no measurable necrosis in response to CSE as 
measured by Annexin/Pi. This is, to my knowledge, the first comparison between 
the apoptotic responses of these two cell types, which suggests, that HLMVECs 
have more robust survival response to CS than SAEC. 
 
1.1.3. CS generates ceramides in vitro 
CSE levels that caused apoptosis were associated with increased 
ceramide levels in both epithelial and endothelial cells, in a dose dependent 
manner. Interestingly, the highest increase of ceramides was observed in 
HLMVEC, cells which also had the highest baseline ceramide levels. This may 
be attributed to acid sphingomyelinase levels, which are the highest in 
endothelial cells. Interestingly, the decrease in the level of ceramides in HLMVEC 
at 10% CSE concentration when compared to 5% might be attributed to complete 
blockage of the de novo ceramide synthesis via DEGS inhibition or to complete 
utilization of available stores of membrane sphingomyelin via activated 
sphingomyelinases. The fact that HLMVEC had the highest ceramide content, 
but were more apt for survival than SAEC suggests that either pro-survival S1P 
is equally robustly increased, or that it is not the total content, but rather the rate 
of increase and the manner of increase in specific ceramides that induce 
apoptosis. 
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1.1.4. CS activates enzymes involved in the synthesis of ceramides 
The upregulation of the de novo and sphingomyelinase pathways by CS 
was cell type-, time-, and concentration-specific. Both ASMase and nSMase 
were briskly activated, whereas SPT and CerS were early on inhibited or 
unaffected, followed by late activation. Epithelial cells relied more on nSMase, 
whereas endothelial cells upregulated ASMase more robustly. 
 
1.2. CS upregulates ceramides in vivo 
1.2.1. Total lung Cer and DHC are increased following chronic CS exposure 
Chronic CS exposure upregulated ceramides along with DHC, indicating 
upregulation of at least the de novo pathway. Fact that the magnitude of DHC 
increase was higher than ceramide increase indicated a partial inhibition of 
DEGS, possibly via oxidative stress. Alternatively, ceramide might be quickly 
utilized for the synthesis of other metabolites. 
1.2.2. Acute CS exposure activates the sphingomyelinase pathway in the 
whole lungs 
Both isoforms of ASMase were found to be upregulated after 1h following 
CS exposure. This data are in agreement with previous reports of quick 
sphingomyelinase activation by stress, including oxidative stress [125]. The 
decrease in CerS5 activity after 1 h of CS exposure may indicate an early 
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inhibition of the de novo pathway, but whether this acute downregulation is due 
to inhibition by DHC or other regulatory processes remains to be determined. 
1.2.3. Chronic CS exposure activates the de novo pathway of ceramide 
synthesis in the whole lung 
The activity of SPT, the first enzyme from the de novo pathway was found 
to be upregulated after 4 months of CS exposure after initial inhibition at 4 weeks 
of CS exposure. These findings correlate well with the occurrence of lung cell 
apoptosis as detected in lung IHC after 4 months of chronic CS. CerS are 
enzymes, which are responsible for the synthesis of various dihydroceramides, 
depending on utilization of specific acyl chains. CerS (LASS) exist in 6 isoforms, 
having specific organ distribution and activity. Interestingly, the expression of 
mRNA level of given CerS does not correspond always with their activity level. Of 
all CerS isoforms, only the mRNA level for CerS2 correlated with its activity 
which was the highest at 6 months of CS exposure. The downregulation of CerS 
mRNA expression early in the CS course may suggest involvement of specific 
transcriptional regulatory mechanisms to prevent overproduction of ceramides or 
DHC in the lungs. My data imply that the de novo pathway is activated by 
prolonged CS exposure, in particular with SPT and CerS2 involvement, with no 
significant coactivation of SMase pathway. However, the timing of harvest of lung 
tissue (16-24 hours) following removal from CS doesn’t exclude a brisk 
participation of sphingomyelinases (minutes) in the generation of ceramides even 
this late in the course of CS exposure. 
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2. Effect of enzyme inhibition on lung apoptosis following CS 
2.1. Inhibition of SPT with Myr does not inhibit lung parenchyma apoptosis 
due to CS 
I noted discordant results between total lung caspase enzymatic activity 
and apoptotic caspase composition by IHC in lungs treated with the SPT 
inhibitor, Myr. This may be explained by the contribution of other lung cells to 
caspase-3 activity. In contrast, IHC only focuses on the lung parenchyma. Only 
on lung parenchyma I detected increases in apoptosis in response to CSE. Myr 
did not decrease it; in contrast it increases apoptosis in response to CS. This 
may suggest that compensatory production of ceramides via neutral 
sphingomyelinases in face of blocked de novo pathway has contributed to 
apoptosis of alveolar cells. 
 
2. 2. Inhibition of ASMase with Amy inhibited lung parenchyma apoptosis 
due to CS 
Amytryptiline is an inhibitor of ASMase accelerating its lysosomal 
degradation. Both ASMase isoforms activated early by CS exposure were 
effectively inhibited by Amy. The i. p. administration of Amy was more effective at 
inhibition of lung ASMase than i. t. administration. Using IHC methodology, we 
demonstrated significant increase in caspase-3 activity following chronic CS. The 
i. p. administration of ASMase inhibitor decreased active caspase-3, induced by 
chronic CSE. Collectively, this data indicate that ceramides produced by ASMase 
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during chronic CS are pro-apoptotic. Although ceramides are produced by both 
de novo and sphingomyelinase pathways, ceramide provided by ASMase, even 
when only briefly activated have a role in triggering caspase-3 activation in 
alveolar parenchyma. 
 
3. RTP801 is required for ceramide-induced cell-specific death in the 
murine lung 
I used in vivo gain of ceramide function approaches, which are 
characterized by alveolar cell apoptosis and oxidative-stress dependent airspace 
enlargement. I have shown that ceramide augmentation induces apoptosis of 
both lung endothelial cells and type II epithelial cells and is associated with 
alveolar wall apoptosis and enlargement of airspaces accompanied by an 
increase in static compliance, suggesting an emphysema phenotype. The 
airspace enlargement was inhibited in mice lacking RTP801, which showed lack 
of apoptosis of epithelial type II cells in response to ceramide. These results 
causally implicate RTP801 as an upstream sensor of lung cellular stresses in 
lung epithelial cells. Although alveolar destruction also involves capillary 
endothelial cells, our data positions type II cells as key in the amplification of the 
alveolar destruction mediated by the interaction of ceramide and RTP801.  
Interestingly, type I cells not only were not protected from apoptosis in the 
RTP801 null mouse, but they exhibited heightened caspase-3 activation in 
response to ceramides. This may suggest a possible crosstalk between stress-
73 
protected alveolar type II cells, which are considered precursors of type I cells, 
and the type I cells, which are bona-fide structural components of the alveolo-
capillary membrane. It is possible that rescued type II cells may replace 
apoptosing type I cells at a rate sufficient to preserve airspace size, and/or that 
RTP801 has opposing roles in the two cell types, being pro-apoptotic in type II 
cells, but anti-apoptotic in type I cells. 
A common denominator linking ceramide and RTP801 upregulation could 
be oxidative stress, a known inducer of both molecules, which is also generated 
downstream of both ceramide and RTP801 upregulation [32, 201, 231, 240]. 
Oxidative stress caused directly by CS or endogenous sources, such as 
inflammatory and parenchymal cells, plays a central unifying roles in all stages of 
emphysema. Reduction in anti-oxidant defenses in NRF-2 knockout mice leads 
to increased susceptibility to emphysema, which is characterized by heightened 
alveolar cell death [241]. Oxidative stress is most likely sensed by a susceptible 
host as a cellular stress in the setting of exposure to CS. RTP801, a negative 
regulator of mTOR signaling, is therefore activated as part of a prototypic 
response to adverse cell stress responses. However, its activation promotes 
cellular injuries triggered by CS, including further oxidative stress, cell death, and 
alveolar inflammation. Excessive ROS could also have been responsible for 
RTP801 increases in response to VEGFR inhibition [234]. In addition, we have 
shown that ceramide-induced airspace enlargement is dependent on oxidative 
stress [201], which may have also upregulated RTP801 in response to intra-
tracheal ceramide administration. 
74 
Ceramide is a prototypic lipid-signaling molecule, which we have shown to 
amplify lung injury due to CS [32, 77, 201, 220, 242]. Prior studies have also 
highlighted that ceramide not only amplifies, but its synthesis is triggered by 
oxidative stress [201]. I present novel evidence that RTP801 is not only sufficient 
but also necessary to mediate increases in lung ceramide via the de novo 
pathway of ceramide synthesis. These data position RTP801 in type II cells as 
upstream of ceramide synthesis in vivo, in settings that reproduce features of 
CS-induced alveolar injury. Of note, increases of lung expression of either 
RTP801 or ceramide levels suffice to lead to alveolar enlargement and alveolar 
cell death. Whether ceramide mediates all or part of RTP801 dependent 
pathogenesis due to CS will await further experimentation in mice deficient of 
ceramide synthetic enzymes. 
The significance of increased airflow resistance in response to ceramide 
upregulation and its attenuation in the RTP801 null animals is yet to be clarified. 
This airway response was associated with increased RTP801 expression in the 
larger airways as well as airway inflammation, as suggested by elevated levels of 
inflammatory cells (PMN) in the bronchoalveolar lavage fluid of wild type animals, 
which was largely RTP801-dependent. The mechanism by which RTP801 
triggers this large airway inflammation is not known. 
The data that VEGF receptor inhibitor also triggers RTP801 expression 
further expands the concept of RTP801 as a stress sensor, in that alterations in 
alveolar maintenance, such as those caused by interruption of VEGF survival 
signals, may be also interpreted as part of a lung cellular stress response. CS 
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has been shown to decrease VEGF signaling in the alveolar lung tissue and 
VEGFR blockade is sufficient to upregulate ceramides, induce oxidative stress, 
and trigger alveolar cell apoptosis, events that precede the onset of airspace 
enlargement [30, 32, 234, 243]. Furthermore, as increases in lung ceramide 
activate RTP801 expression; endogenous lung stress responses may perpetuate 
this pathogenic loop. It will be important to elucidate whether lung injury is more 
severe when these responses become repetitive, possibly exhausting repair 
mechanisms. 
In conclusion, my results highlight the concept of self-amplifying injury in 
response to CS exposure, the role of ASMase activation in lung cell apoptosis, 
the importance of alveolar type II cell apoptosis in this process, and the cell-
specific apoptotic signaling of ceramide in vivo. Early interruption of such self-
perpetuating stress responses may prevent emphysema development, or may 
allow proper repair mechanisms to prevail.  
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F.FUTURE STUDIES 
I demonstrated in vitro and in vivo studies that ceramides play an 
important role in the development of lung cell apoptosis in response to CS.  
There are still many unanswered questions. Lungs consist of more than 50 
different cell types and there are multiple complex interactions between them, 
including various type of signaling. Both epithelial and endothelial cells from 
alveolar units are the first line of cells responsible for apoptotic changes due to 
harmful insults, including CS exposure. In vitro studies, although well conducted, 
can delineate only some aspects of pathophysiologic changes due to exogenous 
insults, including CS exposure. In vivo, when embedded in a complex 
microenvironment, particular cells responses to noxious stimuli may differ to 
those observed in vitro. This is specifically important when studying ceramide 
synthesis due to CS exposure.  Particular cells may differ in the way they 
synthesize ceramides. Even the same cells can activate different biosynthetic 
pathways depending on stimulus. For example, endothelial cells may produce 
ceramides acutely via acid spingomyelinase activity due to CS exposure or TNF-
α, which can eventually activate the de novo pathway. Thus, further studies on 
particular cell lines in vivo, using sorted cells following rapid lung disintegration 
may be needed for precise cell-specific kinetics of ceramide activation and 
apoptosis. 
Other studies should be directed for biochemical compounds for targeted 
inhibition of pathways for ceramide synthesis. Pharmacological inhibition of the 
enzymes involved in the synthesis of ceramides could have off target effects. 
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Furthermore, since ceramides are important intermediaries for more complex 
sphingolipids, including those responsible for activating pro-survival pathways, 
the inhibition of ceramide synthetic patways may lead to scarcity of ceramides in 
certain cells, and paradoxically, to enchanced apoptosis. For this reason 
research should be directed to specifically inhibit the synthesis of ceramides only 
in these cells which are extremaly sensitive to ceramides. 
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Figure 1. Proliferation assay performed on rat lung endothelial cells following CS 
exposure. That assay was determined with BrdU incorporation using ELISA. (A) 
Proliferation of cells exposed for 48h to the indicated concentrations of CSE. 
Mean +SEM; * p,0.05; n=3. (B) Proliferation of cells exposed to CS (2.5% CSE)  
for the indicated time. Mean +SEM; #: p<0.01; n=3. AC - air control; CS - 
cigarette smoke. 
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Figure 2. Evaluation of apoptosis events in lung alveolar cells following different 
CS exposure. Apoptotic events were quantified by Annexin-V/PI staining and flow 
cytometry. (A) Apoptosis measured in small airway epithelial cells (SAEC) 
following CS exposure (0.1 to 10% CSE) for 6 h. Mean+ SEM; *: p<0.05, 
ANOVA; n=2-3/group. (B) Apoptosis measured in human lung microvascular 
epithelial cells (HLMVEC) following CS exposure (0.1 to 10% CSE) for 6 h. 
Mean+ SEM; ANOVA; n=2/ each concentration.  
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Figure 3. Ceramide content of lung cells following CS exposure. Total ceramides 
levels in lung microvascular endothelial cells (HLMVEC) or small airway epithelial 
cells (SAEC) exposed to CS (0.1, 1, 5, 10%) for 24 h. Mean+ SEM; *p<0.05; 
n=3/HLMVEC and 5/SAEC/group. 
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Figure 4. Effect of CS exposure on the activity on the sphingomyelinase pathway 
in cultured human lung endothelial cells. Cultured cells were exposed to CS (5 or 
10%) for the indicated time. (A) The lysosomal ASMase activity, (B) secreted 
ASMase activity, and (C) neutral SMase activity, were expressed as activity rates 
normalized by protein concentration. Mean+ SEM; n=2-3/group. 
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Figure 5. Effect of CS exposure on the enzymatic activities in the de novo 
ceramide synthesis pathway in rat lung epithelial cells. Cultured cells were 
exposed for the indicated time to CS (5 and 10% CSE). (A) SPT activity was 
expressed as arbitrary units (AU) derived from the number of scintillation counts 
per minute, normalized by the protein concentration of the sample. Mean+ SEM; 
n=2-3/group. (B) Ceramide synthase-5 activity was expressed as AU derived 
from densitometric density of TLC bands, normalized by the protein 
concentration. Mean+ SEM; n=2-3/group. (C) Ceramide synthase-2 activity was 
expressed as AU derived from densitometric density of TLC bands, normalized 
by the protein concentration. Mean+ SEM; n=2-3/group. 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
C
er
am
id
e 
sy
nt
ha
se
 2
ac
tiv
ity
 
(A
U
/µ
g)
CON     1h    4h      24h     1h      4h     24h    neg
Lung epithelial cells
5% CS           10% CS
C
86 
 
 
 
 
 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
CON 1h       4h       24h     1h        4h      24h
5% CSE                     10% CSE
Ly
so
so
m
al
 A
S
M
ac
tiv
ity
(m
U
/m
in
/ µ
g)
Lung epithelial cells
A
*
0
1
2
3
4
5
6
7
8
9
CON        1h          4h          1h          4h
S
ec
re
te
d 
A
S
M
ac
tiv
ity
(m
U
/m
in
/ µ
g)
5% CS              10% CS
Lung epithelial cellsB
87 
 
 
Figure 6. Effect of CS exposure on the activity of enzymes in the 
sphingomyelinase pathway in rat lung epithelial cells. A-C: Cultured rat lung 
epithelial cells (L2) were exposed for the indicated time to CS (5 and 10% CSE). 
(A) Lysosomal ASMase activity; (B) secreted ASMase activity; and (C) neutral 
SM activity were each normalized to protein concentration. Mean+ SEM; n=2-
3/group. *: p<0.05, ANOVA. 
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Figure 7. CS exposure increases production of ceramides in vivo. Lung 
ceramide levels in response to CS exposure for 4 weeks in C57Bl/6 mice. Left 
panel: total ceramide level adjusted to lipid phosphorus concentration. Mean+ 
SEM; p<0.05 vs. control AC; n=5/group. Right panel: total dihydroceramide level 
adjusted to lipid phosphorus concentration. Mean+ SEM; p<0.05 vs. control AC; 
n=5/group. Ceramide content was evaluated by Walter Hubbard, JHU. 
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Figure 8. Determination of enzymatic activities in sphingomyelinase ceramide 
synthesis pathway in both endothelial and epithelial cells type I isolated from 
enzymatically disintegrated lungs, following 1 week of CS exposure. (A) Design 
for the experiment: DBA2/J mice were exposed to CS for 1 week, lungs were 
enzymatically disintegrated and sorted for endothelial and epithelial type I cells. 
In both groups of cells the activities of lysosomal ASMase, neutral SMase and 
caspase-3 were determined. (B) Lysosomal ASMase activity in endothelial cells 
normalized to protein concentration. Mean+ SEM; n=4-5/group. (C) Neutral 
SMase activity in endothelial cells normalized to protein concentration. Mean+ 
SEM; n=4-5/group (D) Caspase-3 activity in endothelial cells (measured in 16.86 
µg of protein per sample). Mean+ SEM; * p< 0.05; n=4-5/group. (E) Neutral 
SMase activity in epithelial cells type I normalized to protein concentration. 
Mean+ SEM; * p< 0.05; n=4-5/group. (F) Caspase-3 activity in epithelial cells 
type I (measured in 16.86 µg of protein per sample). Mean+ SEM; * p< 0.05; n=4-
5/group. 
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Figure 9. Effect of short term CS exposure on the activity of ceramide synthesis 
enzymes in the whole lung tissue of DBA2/J mice. (A) Experimental design for 
acute CS exposure in. (B) Lysosomal and secreted acid sphingomyelinase 
activities normalized by protein concentration. Mean+ SEM; * p<0.05; n=5/group. 
(C) Lysosomal and (D) neutral sphingomyelinase activities normalized by protein 
concentration. Mean+ SEM; * p<0.05; n=4/group. (E) Ceramide syntase 5 activity 
expressed as arbitrary units calculated from densitometry units normalized to 
protein concentration. Mean+ SEM; n=5/group. 
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Figure 10. Effect of CS on enzymes of the de novo ceramide synthesis pathway 
in the whole lungs. Mice (DBA2/J) were exposed to CS for the indicated time and 
SPT activity was determined using tritium-labeled L-serine and expressed as 
arbitrary units normalized by protein concentration. Mean+ SEM; p< 0.05; 
n=3/group. 
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Figure 11. Expression of mRNA levels of distinct lung ceramide synthase 
isoforms in the whole lung of C57Bl6 mice following CS exposure for the 
indicated time. (A-F) mRNA levels  were measured by real time PCR. For all 
panels: Mean+ SEM; * p< 0.05 vs. air control; n=5. Data provided by Dr. A. 
Futerman (Weizmann Institute, Israel). 
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Figure 12. CS exposure activates enzymes of the de novo pathway in the lungs 
of DBA2/J mice. (A) Ceramide synthase 2 activity in lungs of DBA2/J mice, 
expressed as arbitrary units (AU) of densitometry normalized by protein 
concentration. Mean+ SEM; p< 0.05 vs. AC; n=5/group. (B) Ceramide synthase 5 
activity in lung of DBA2/J mice, expressed as arbitrary units (AU) of densitometry 
normalized by protein concentration. Mean+ SEM; p< 0.05 vs. AC; n=5/group. 
(C) Activity levels of lung ceramide synthase 5 in C57Bl/6 mice during chronic CS 
exposure, expressed as arbitrary units (AU) of densitometry normalized by 
protein concentration. Mean+ SEM; p< 0.05 vs. AC; n=5/group. 
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Figure 13. Effect of CS exposure on the activity of enzymes in the 
sphingomyelinase pathway in the whole lung tissue of DBA2/J mice. (A) 
Lysosomal acid sphingomyelinase, (B) soluble acid sphingomyelinase, and (C) 
Neutral sphingomyelinase activities were measured following CS exposure for 
the indicated time and were normalized by protein concentration. Mean+ SEM; 
n=4/group.  
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Figure 14. Effect of the ASMase inhibitor amytryptilline (Amy) on the lysosomal 
and secreted ASMase activities induced by short term CS exposure in lungs of 
DBA2/J mice. (A) Experimental design: mice were intratracheally instilled or 
intraperitoneally injected with Amy (0.3 mg/kg, once) or with vehicle (PBS) 1 h 
prior to exposure to CS (for 1 h). Whole lung (B) lysosomal and (C) secreted 
sphingomyelinases activities were normalized to protein concentration. Mean + 
SEM; * p<0.05; n=4/group. 
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Figure 15. Effect of ASMase inhibition with amytryptilline on lung apoptosis 
following chronic CS exposure in DBA2/J mice. (A) Experimental design. (B) 
Caspase-3 activity measured by IHC with active caspase-3 antibody and image 
analysis of lung parenchyma only. Boxplot (box indicating the 25th and 75th 
percentile with the middle line showing the median and the 5th and 95th 
percentiles indicated by whiskers); Abbreviations: AmyP: Amy prophylactic, 
AmyT: Amy treatment, AmyC: Amy Control: ANOVA; *p<0.05; n=5-10/group. 
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Figure 16. Effect of SPT inhibition with myriocin on lung apoptosis following 
chronic CS exposure of DBA2/J mice. (A) Experimental design. (B) Whole lung 
SPT activity expressed as arbitrary units (AU) derived from scintillation counts, 
normalized to 50 mg tissue protein. Mean + SEM; n=4-5/group. (C) Whole lung 
neutral SMase activity normalized to protein concentration. Mean+ SEM; p<0.05; 
n=4-5/group. (D-E) Apoptosis measured via caspase-3 activity in the whole lung 
tissue normalized per 11.49 ug protein (D) or specifically in the lung parenchyma 
by immunohistochemistry (E) using active caspase-3 antibody and image 
analysis. Mean+ SEM; * p<0.05; n=4-5/group.  
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Figure 17. Elevation of lung RTP801 is associated with increases of airspace 
size, apoptosis, and ceramide levels. (A) In a model of apoptosis-dependent 
emphysema by vascular growth factor receptor inhibition expression of RTP801 
is increased in the lung tissue. RTP801 protein expression was measured by 
Western blotting in lung homogenates from individual mice treated with SU5416 
(20 mg/kg; s. c. once) and harvested after the indicated number of days, with 
vehicle control (Veh; s.c. once, lungs harvested at day 7), or with SU5416 and 
ceramide synthase inhibitor Fumonisin B1 (FB1; 1.1 mg/kg, i.p. daily; lungs 
harvested at day 7). Each lane represents a different mouse lung. Vinculin 
immunoblotting was used as a loading control. (B-E) Effects of intra-tracheal 
instillation (i-t) of RTP801-expressing plasmid (50 mg) in the lung: (B) Increased 
RTP801 protein measured in the lung homogenates by Western blot following 
RTP801 instillation compared to control plasmid. (C): The left panel shows active 
caspase-3 positive cells detected by immunohistochemistry (brown; arrow) in 
fixed lung tissue from control animals following intra-tracheal instillation of empty 
plasmid (50 mg; lungs harvested after 3 days) or of RTP801-plasmid; size bar 10 
mm. The right panel represents quantification of data from IHC; Mean + SEM, 
*p<0.05 vs. control; Student’s t test; n=3 mice/group; 8-10 lung fields/mouse). (D) 
Airspace enlargement was measured by morphometry of the hematoxyllin-eosin-
stained fixed lungs (inset) 3 days after RTP801-plasmid instillation and 
expressed as the mean frequency of alveoli of a certain diameter. Note a shift the 
right (towards a higher frequency of larger diameter alveoli) in mice instilled with 
RTP801-plasmid (grey line) compared to control (black line); n=3/group. (E) Total 
111 
ceramide content of mouse lungs at 3 days following RTP801-plasmid instillation, 
with or without ceramide synthase inhibitor fumonisin B1 (FB1; 2.2 mg/kg), 
measured by DAG kinase assay and expressed as arbitrary units (from 
densitometric analysis of ceramide on TLC plates) normalized by lipid inorganic 
phosphorus (lipid Pi). Mean + SEM, *p<0.05; ANOVA; n=3-5/group. 
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Figure 18. Increases in lung ceramide content are associated with airspace 
enlargement, apoptosis, and RTP801 upregulation. Effect of a single intra-
tracheal instillation of ceramide C12:0 (A-D) or C16:0 (E-F) (5 mg/kg) in mice on: 
(A) Endogenous ceramides/sphingosine-1 phosphate (S1P) ratio in lung tissue 
homogenates at the indicated time in sham-operated mice (that underwent 
exposure of the trachea only), negative control mice (that were administered the 
vehicle only) or mice that received exogenous C12:0. Boxplot (box indicating the 
25th and 75th percentile with the middle line showing the median and the 5th and 
95th percentiles indicated by whiskers); ANOVA; *p<0.05; n=4-5/group.(B) Lung 
caspase-3/7 enzymatic activity was measured in whole lung lysates of mice that 
were instilled with C12:0 (n=7) and expressed relative to the activity measured in 
control mice (n=5). Mean ± SEM; *: p<0.05 vs. control; Student’s t test). (C) Lung 
active caspase-3 expression detected by IHC (brown, arrows) shown in 
representative micrographs (size bar 50 mm). (D) Lung surface/volume ratio 
determined by standardized lung morphometry of alveolar spaces of mice 
following ceramide instillation timecourse and 48h, respectively. Boxplot, 
ANOVA; * P<0.05; n=2 (Sham); n=3-4/group; 8-10 lung fields/mouse. (E) 
RTP801 expression detected by IHC in the lung sections of mice following C16: 0 
instillation compared to control animals or rtp801-null mice. Note an increase in 
RTP801 (brown, arrows) in the lung parenchyma and also (see insets) in the 
vascular (v) endothelium as well as bronchial (b) epithelium in ceramide-instilled 
mice. (F) RTP801 expression in the lung parenchyma was quantified via blinded 
image analysis software and expressed as arbitrary units (AU); Mean + SEM, *: 
115 
p<0.05, Student’s t test; n=4, except for RTP801-null mice, which was n=2; 8-10 
lung field/mouse. 
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Figure 19. Requirement for RTP801 in ceramide-induced apoptosis of type II 
epithelial cells and neutrophil infiltration. (A) Caspase-3/7 activity levels in whole 
lungs homogenates normalized by protein concentration. Mean + SEM; *: 
p<0.05; Student’s t test; n=2-4/group. (B) Cell specific apoptosis expressed as 
relative abundance (%) apoptotic active caspase-3/7- positive cells among lung 
endothelial (CD31-positive), alveolar epithelial type I (podoplanin positive) and 
type II (pro-surfactant-C positive) cells in murine lung cell suspensions, detected 
by flow cytometry with fluorescence-labeled specific antibodies. Mean + SEM; *: 
p<0.05; n=4-5/group. Note that only type II epithelial cells were protected against 
ceramide-induced apoptosis in rtp801-null mice. (C-D) Analysis of abundance (% 
of total cells) of polymorphonuclear cells (PMN), (C) and alveolar macrophages 
(D) counted in cytospins of the bronchoalveolar lavage fluid in mice. Mean + 
SEM, *: p<0.05; n=4-5/group. 
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Figure 20. Requirement for RTP801 in ceramide-induced changes of lung 
alveolar morphology and function. (A-D) Measurements in response to 
exogenous ceramide 16:0 (5mg/kg; 48 h) or vehicle (control) intra-tracheal 
instillation in wild type or rtp801-null mice. (A-B) Mean linear intercept (MLI); (A) 
expressed as boxplot (box indicating the 25th and 75th percentile with the middle 
line showing the median; the 5th and 95th percentiles indicated by whiskers; n=5; 
* NS
*      NSD
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8-10 lung fields/mouse) measured by automated morphometry of lung 
parenchyma on paraffin embedded lung sections stained with hematoxyllin-eosin 
(B). (C) Lung compliance measured with Flexivent in anesthetized mice; Box 
plot; n=4 (wild type) or 5 (rtp801-null). Two-way ANOVA; *: p<0.05 or NS (not 
statistically significant). (D) Airflow resistance measured with Flexivent in 
anesthetized mice. Two-way ANOVA: * p<0.05 or NS (not statistically significant); 
n=5/group. 
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